Enzo Biochem (ENZ) 10-K 27 Sep 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2017	Sep. 18, 2017	Jan. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-K
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		46,547,898
Entity Public Float			$ 287,683,000
Amendment Flag	false
Entity Central Index Key	316,253
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jul. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Current assets:
Cash and cash equivalents	$ 64,167	$ 67,777
Accounts receivable, net of allowance for doubtful accounts of $3,576 in 2017 and $3,517 in 2016	15,180	14,592
Inventories	7,047	6,971
Prepaid expenses	2,690	2,057
Total current assets	89,084	91,397
Property, plant, and equipment, net	7,901	8,214
Goodwill	7,452	7,452
Intangible assets, net	2,895	4,422
Other	333	336
Total assets	107,665	111,821
Current liabilities:
Loan payable		1,557
Accounts payable - trade	10,350	9,857
Accrued liabilities	6,720	8,211
Other current liabilities	740	943
Total current liabilities	17,810	20,568
Other liabilities	983	1,699
Total liabilities	18,793	22,267
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 46,506,176 at July 31, 2017 and 46,267,619 at July 31, 2016	465	463
Additional paid-in capital	328,294	326,288
Accumulated deficit	(241,900)	(239,396)
Accumulated other comprehensive income	2,013	2,199
Total stockholders’ equity	88,872	89,554
Total liabilities and stockholders’ equity	$ 107,665	$ 111,821

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Allowance for doubtful accounts (in Dollars)	$ 3,576	$ 3,517
Preferred Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred Stock, shares authorized	25,000,000	25,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common Stock, shares authorized	75,000,000	75,000,000
Common Stock, shares issued	46,506,176	46,267,619
Common Stock, shares outstanding	46,506,176	46,267,619

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Revenues:
Clinical laboratory services	$ 77,407	$ 70,915	$ 63,414
Product revenues	29,192	30,337	31,690
Royalty and license fee income	1,205	1,521	2,495
Total revenues	107,804	102,773	97,599
Operating costs, expenses and legal settlements, net:
Cost of clinical laboratory services	45,400	42,859	39,589
Cost of product revenues	14,078	14,331	15,183
Research and development	2,928	3,524	3,350
Selling, general, and administrative	44,010	43,586	41,069
Provision for uncollectible accounts receivable	2,775	2,336	2,284
Legal fee expense	1,679	6,384	8,788
Legal settlements, net		(57,250)	(11,458)
Total costs, expenses and legal settlements, net	110,870	55,770	98,805
Operating (loss) income	(3,066)	47,003	(1,206)
Other income (expense):
Interest	384	(136)	(245)
Other	125	122	95
Foreign exchange gain (loss)	135	(474)	(936)
(Loss) income before income taxes	(2,422)	46,515	(2,292)
(Provision) benefit for income taxes	(82)	(1,229)	7
Net (loss) income	$ (2,504)	$ 45,286	$ (2,285)
Net (loss) income per common share:
Basic (in Dollars per share)	$ (0.05)	$ 0.98	$ (0.05)
Diluted (in Dollars per share)	$ (0.05)	$ 0.97	$ (0.05)
Weighted average common shares outstanding:
Basic (in Shares)	46,350	46,153	45,355
Diluted (in Shares)	46,350	46,602	45,355

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Net (loss) income	$ (2,504)	$ 45,286	$ (2,285)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(186)	338	117
Comprehensive (loss) income	$ (2,690)	$ 45,624	$ (2,168)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Jul. 31, 2014	$ 443	$ 317,160	$ (282,397)	$ 1,744	$ 36,950
Balance (in Shares) at Jul. 31, 2014	44,239,183
Net income (loss) for the year ended			(2,285)		(2,285)
Vesting of restricted stock (in Shares)	19,418
Share-based compensation charges		429			429
Net proceeds from Issuance of common stock (net of expenses of $207)	$ 16	6,672			6,688
Net proceeds from Issuance of common stock (net of expenses of $207) (in Shares)	1,588,480
Issuance of options in lieu of payment of cash bonuses		45			45
Issuance of common stock for employee 401(k) plan match	$ 2	660			662
Issuance of common stock for employee 401(k) plan match (in Shares)	214,984
Foreign currency translation adjustments				117	117
Balance at Jul. 31, 2015	$ 461	324,966	(284,682)	1,861	42,606
Balance (in Shares) at Jul. 31, 2015	46,062,065
Net income (loss) for the year ended			45,286		45,286
Vesting of restricted stock (in Shares)	11,500
Share-based compensation charges		525			525
Issuance of options in lieu of payment of cash bonuses					0
Issuance of common stock for employee 401(k) plan match	$ 2	707			709
Issuance of common stock for employee 401(k) plan match (in Shares)	160,352
Exercise of stock options		90			$ 90
Exercise of stock options (in Shares)	33,702				33,702
Foreign currency translation adjustments				338	$ 338
Balance at Jul. 31, 2016	$ 463	326,288	(239,396)	2,199	89,554
Balance (in Shares) at Jul. 31, 2016	46,267,619
Net income (loss) for the year ended			(2,504)		(2,504)
Vesting of restricted stock (in Shares)	5,140
Share-based compensation charges		831			831
Issuance of options in lieu of payment of cash bonuses					0
Issuance of common stock for employee 401(k) plan match	$ 1	723			724
Issuance of common stock for employee 401(k) plan match (in Shares)	91,541
Exercise of stock options	$ 1	452			$ 453
Exercise of stock options (in Shares)	141,876				141,876
Foreign currency translation adjustments				(186)	$ (186)
Balance at Jul. 31, 2017	$ 465	$ 328,294	$ (241,900)	$ 2,013	$ 88,872
Balance (in Shares) at Jul. 31, 2017	46,506,176

CONSOLIDATED STATEMENTS OF STO7

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parentheticals) $ in Thousands	12 Months Ended
	Jul. 31, 2015USD ($)
Issuance of common stock, expenses	$ 207
Common Stock [Member]
Issuance of common stock, expenses	207
Additional Paid-in Capital [Member]
Issuance of common stock, expenses	$ 207

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (2,504)	$ 45,286	$ (2,285)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization of property, plant and equipment	2,078	2,163	2,019
Amortization of intangible assets	1,520	1,677	1,770
Provision for uncollectible accounts receivable	2,775	2,336	2,284
Deferred income tax benefit		(60)	(104)
Share-based compensation charges	831	525	429
Share-based 401(k) employer match expense	724	709	662
Foreign exchange (gain) loss	(476)	357	664
Changes in operating assets and liabilities:
Accounts receivable	(3,244)	(4,791)	(2,003)
Other receivables - settlements		6,650	(6,650)
Inventories	92	466	1,151
Prepaid expenses	(618)	169	(108)
Accounts payable - trade	515	1,103	394
Accrued liabilities, other current liabilities and other liabilities	(1,898)	(3,464)	(1,923)
Total adjustments	2,299	7,840	(1,415)
Net cash (used in) provided by operating activities	(205)	53,126	(3,700)
Cash flows from investing activities:
Capital expenditures	(1,753)	(1,530)	(1,783)
Decrease in security deposits and other	4	18	31
Net cash used in investing activities	(1,749)	(1,512)	(1,752)
Cash flows from financing activities:
Net proceeds from issuance of common stock			6,688
Proceeds from borrowings under Credit Agreement	40,694	89,880	88,632
Repayments under Credit Agreement	(42,250)	(91,336)	(88,632)
Installment loan payments	(566)	(565)	(463)
Proceeds from exercise of stock options	453	90
Net cash (used in) provided by financing activities	(1,669)	(1,931)	6,225
Effect of exchange rate changes on cash and cash equivalents	13	(15)	(119)
(Decrease) increase in cash and cash equivalents	(3,610)	49,668	654
Cash and cash equivalents - beginning of year	67,777	18,109	17,455
Cash and cash equivalents - end of year	$ 64,167	$ 67,777	$ 18,109

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	Note 1 - Summary of significant accounting policies Nature of business Enzo Biochem, Inc. (the “Company”) is an integrated life science and biotechnology company engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Company’s technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides molecular and esoteric diagnostic medical testing services in the New York and New Jersey medical communities. The Company operates in three segments (see Note 15). Principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc. (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Inc. and Enzo Realty LLC (“Realty”). All intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates. Foreign Currency Translation/Transactions The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations. Cash and cash equivalents Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At July 31, 2017 and 2016, the Company had cash and cash equivalents in foreign bank accounts of $0.5 million. Fair Values of Financial Instruments The recorded amounts of the Company’s cash and equivalents, receivables, loan payable, accounts payable and accrued liabilities approximate their fair values principally because of the short-term nature of these items. Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. Concentration of credit risk with respect to the Company’s Life Sciences segment is mitigated by the diversity of the Company’s clients and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited. The Company believes that the concentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of third party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation. Accrual for Self-Funded Medical Accruals for self-funded medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted. Revenue Recognition - Product revenues Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured. Royalties Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues. Clinical laboratory services Revenues from the Clinical Labs segment are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected reimbursable settlements from such payers. The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: Years Ended July 31, 2017 2016 2015 Revenue category Amount % Amount % Amount % Third-party payers $ 43,059 56 $ 34,454 49 $ 30,685 49 Patient self-pay 11,380 15 14,744 21 11,028 17 Medicare 12,705 16 11,392 16 11,981 19 HMO’s 10,263 13 10,325 14 9,720 15 Total $ 77,407 100 % $ 70,915 100 % $ 63,414 100 % The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs (See Note 14). Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 39%, 30% and 28% of the Clinical Labs segment net revenue for the years ended July 31, 2017, 2016 and 2015 respectively. Contractual Adjustment The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule the Company sets for all third-party payers, including Medicare, HMO’s and managed care providers. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company. During the years ended July 31, 2017, 2016 and 2015, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were approximately 84%, 84% and 85%, respectively, of gross billings. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue. For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future accounting periods based on write-offs during those periods. It bases the estimate for the allowance on the evaluation of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection include the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received from the ordering physician which results in denials of payment, and our estimate of the uncollected portion of receivables from self-payers, including deductibles and copayments, which are subject to credit risk and patients’ ability to pay. The Company fully reserves through its contractual allowances amounts that have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis for recoveries, if any, on an on-going basis. The Company’s ability to collect outstanding receivables from third-party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection issues and to assess the impact, if any, on the allowance estimates which involves judgment. The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount. The allowance for doubtful accounts as a percentage of total accounts receivable at July 31, 2017 and 2016 was 19.1% and 19.4% respectively. The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At July 31, 2017 and 2016, approximately 75% and 71%, respectively, of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York and New Jersey medical communities. The Life Sciences segment’s accounts receivable includes royalties receivable of $0.4 million and $0.5 million, as of July 31, 2017 and 2016, respectively, due from QIAGEN Gaithersburg Inc. (“Qiagen”) (see Note 12). The following is a table of the Company’s net accounts receivable by segment. July 31, 2017 July 31, 2016 Net accounts receivable by segment Amount % Amount % Clinical Labs (by billing category) Third party payers $ 7,256 64 $ 5,861 57 Patient self-pay 1,591 14 1,676 16 Medicare 1,385 12 1,486 14 HMO’s 1,169 10 1,341 13 Total Clinical Labs 11,401 100 % 10,364 100 % Total Life Sciences 3,779 4,228 Total accounts receivable – net $ 15,180 $ 14,592 Changes in the Company’s allowance for doubtful accounts are as follows: July 31, 2017 July 31, 2016 Beginning balance $ 3,517 $ 1,786 Provision for doubtful accounts 2,775 2,336 Write-offs (2,716 ) (605 ) Ending balance $ 3,576 $ 3,517 Inventories The Company values inventory at the lower of cost (first-in, first-out) or net realizable value, which approximates market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations. Property, plant and equipment Property, plant and equipment is stated at cost, and depreciated on the straight-line basis over the estimated useful lives of the various asset classes as follows: building and building improvements: 15-30 years, and laboratory machinery and equipment and office furniture and computer equipment which range from 3-10 years. Leasehold improvements are amortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter. Goodwill and Intangible Assets Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. Intangible assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. Indefinite-lived intangibles are not amortized and are evaluated each reporting period to determine whether events and circumstances continue to support their having an indefinite life. Indefinite-lived intangibles found to no longer have an indefinite life are evaluated for impairment and are then amortized over their remaining useful life as finite-lived intangible assets. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed. Impairment testing for Goodwill and Long-Lived Assets The Company tests goodwill annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill for impairment, the Company has the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less than its fair value, no impairment exists and the second step is not performed. If the carrying amount of the reporting unit is higher than its fair value, the second step must be performed to compute the amount of the goodwill impairment. In the second step, the impairment charge is the amount by which the carrying amount exceeds the reporting unit’s fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company performed a quantitative assessment in 2017 and a qualitative assessment in 2016 and 2015, and concluded there were no goodwill impairments. The Company reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives) for impairment annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of an asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value. There were no long-lived asset impairments in 2017, 2016 or 2015. Comprehensive income (loss) Comprehensive income (loss) consists of the Company’s consolidated net income (loss) and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive income (loss) were not tax effected as investments in international affiliates are deemed to be permanent. Accumulated other comprehensive income is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments. Shipping and Handling Costs Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold. Research and Development Research and development costs are charged to expense as incurred. Advertising All costs associated with advertising are expensed as incurred. Advertising expense, included in selling, general and administrative expense, approximated $649, $601 and $556 for the years ended July 31, 2017, 2016 and 2015, respectively. Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At July 31, 2017, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Segment Reporting The Company separately reports information about each operating segment that engages in business activities from which the segment may earn revenues and incur expenses, whose separate operating results are regularly reviewed by the chief operating decision maker regarding allocation of resources and performance assessment and which exceed specific quantitative thresholds related to revenue and profit or loss. The Company’s operating activities are reported in three segments (see Note 15). Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Diluted weighted average shares outstanding for fiscal 2017 and 2015 do not include the potential common shares from stock options and unvested restricted stock because to do so would have been antidilutive and as such is the same as basic weighted average shares outstanding for 2017 and 2015. For fiscal 2016, approximately 449,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. The number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted weighted average shares outstanding for the years ended July 31, 2017, and 2015 was 961,000, and 403,000, respectively. For the years ended July 31, 2017, 2016 and 2015, the effect of approximately zero, 282,000 and 977,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: 2017 2016 2015 Net (loss) income $ (2,504 ) $ 45,286 $ (2,285 ) Weighted-average common shares outstanding - basic 46,350 46,153 45,355 Add: effect of dilutive stock options and restricted stock — 449 — Weighted-average common shares outstanding - diluted 46,350 46,602 45,355 Net (loss) income per share – basic $ (0.05 ) $ 0.98 $ (0.05 ) Net (loss) income per share – diluted $ (0.05 ) $ 0.97 $ (0.05 ) Share-Based Compensation The Company records compensation expense associated with stock options and restricted stock based upon the fair value of stock based awards as measured at the grant date. The Company determines the award values of stock options using the Black Scholes option pricing model. The expense is recorded by amortizing the fair values on a straight-line basis over the vesting period, adjusted for forfeitures. For the years ended July 31, 2017, 2016 and 2015, share-based compensation expense relating to the fair value of stock options, restricted shares and restricted stock units was approximately $831, $525, and $429, respectively (see Note 10). No excess tax benefits were recognized for the year ended July 31, 2016, 2015 and 2014. The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: 2017 2016 2015 Cost of clinical laboratory services $ 6 $ 6 $ 5 Research and development — — 2 Selling, general and administrative 825 519 422 $ 831 $ 525 $ 429 As of July 31, 2017, there was $1,187 of total unrecognized compensation cost related to non-vested share-based payment arrangements granted under the Company’s incentive stock plans, which will be recognized over a weighted average remaining life of approximately seventeen months. Effect of New Accounting Pronouncements Recently Adopted Accounting Pronouncements In November 2015, the FASB issued ASU 2015-17, Income Taxes – Balance Sheet Classification of Deferred Taxes In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment Pronouncements Issued but Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In May 2017, the FASB issued ASU 2017-09, “ Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.

Goodwill and intangible assets

Goodwill and intangible assets	12 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 2 - Goodwill and intangible assets Goodwill The Company’s net carrying amount of goodwill is in the Clinical Labs segment and is $7,452 as of July 31, 2017 and 2016. Intangible assets The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155 Amortization expense — (1,677 ) (1,677 ) Foreign currency translation (188 ) 132 (56 ) July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (1,520 ) (1,520 ) Foreign currency translation (214 ) 207 (7 ) July 31, 2017 $ 27,436 $ (24,541 ) $ 2,895 Intangible assets, all finite-lived, consist of the following: July 31, 2017 July 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Patents $ 11,027 $ (10,951) $ 76 $ 11,027 $ (10,905) $ 122 Customer relationships 11,881 (9,083) 2,798 12,122 (8,331) 3,791 Website and acquired content 1,011 (1,011) — 1,011 (1,011) — Licensed technology and other 484 (463) 21 485 (437) 48 Trademarks 3,033 (3,033) — 3,005 (2,544) 461 Total $ 27,436 $ (24,541) $ 2,895 $ 27,650 $ (23,228) $ 4,422 At July 31, 2017 information with respect to the intangibles acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 3 years Trademarks 5 years — Other intangibles 10 years 2 years At July 31, 2017, the weighted average remaining useful life of intangible assets was approximately two years. Estimated amortization expense related to these finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows: 2018 $ 980 2019 829 2020 501 2021 266 2022 229 Amortization expense for the years ended July 31, 2017, 2016, and 2015 was $1,520, $1,677, and $1,770, respectively.

Supplemental disclosure for sta

Supplemental disclosure for statement of cash flows	12 Months Ended
	Jul. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	Note 3 - Supplemental disclosure for statement of cash flows In the years ended July 31, 2017, 2016, and 2015, income taxes paid by the Company approximated $1,021, $279, and $115 respectively . In the years ended July 31, 2017, 2016, and 2015, interest paid by the Company approximated $119, $121, and $206 respectively. During fiscal 2017, 2016 and 2015, the Company financed $69, $95 and $346, respectively, in machinery and transportation equipment under installment loans. During fiscal 2017, the Company did not enter into any capital lease agreements. During fiscal 2016 and 2015, the Company entered into capital lease agreements for machinery and equipment with a cost basis of $1,280 and $155, respectively. During fiscal 2015, the Company recorded $45 in additional paid in capital and reduced accrued liabilities by the same amount for options issued in lieu of cash payment of certain incentive compensation awards. There were no such transactions recorded during fiscal 2017 or 2016.

Inventories

Inventories	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories Inventories consisted of the following at July 31: 2017 2016 Raw materials $ 852 $ 951 Work in process 1,905 1,755 Finished products 4,290 4,265 $ 7,047 $ 6,971

Property, plant, and equipment

Property, plant, and equipment	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property, plant, and equipment At July 31, 2017 and 2016 property, plant, and equipment consist of: 2017 2016 Building and building improvements $ 4,898 $ 4,915 Machinery and equipment (includes asset under capital lease - see Note 9) 7,878 7,479 Office furniture and computer equipment 19,434 19,765 Leasehold improvements 5,389 5,172 37,599 37,331 Accumulated depreciation and amortization (30,410 ) (29,829 ) 7,189 7,502 Land and land improvements 712 712 $ 7,901 $ 8,214

Income taxes

Income taxes	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 6 - Income taxes The (provision) benefit for income taxes for fiscal years ended July 31 is as follows: 2017 2016 2015 Current (provision) benefit: Federal $ - $ (968 ) $ — State and local (70) (276 ) (72 ) Foreign (12) (45 ) (25 ) Deferred benefit - 60 104 Benefit (provision) for income taxes $ (82) $ (1,229 ) $ 7 Deferred tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferred tax assets (liabilities) as of July 31 are as follows: 2017 2016 Deferred tax assets: Federal tax carryforward losses $ 18,831 $ 18,964 Provision for uncollectible accounts receivable 1,392 1,406 State and local tax carry forward losses — 2,757 Accrued royalties 149 146 Stock compensation 782 616 Depreciation 804 769 Research and development and other tax credit carryforwards 2,208 2,152 Foreign tax carryforward losses 2,420 2,046 Intangibles 2,888 2,915 Inventory 2,536 2,477 Accrued expenses 1,420 1,321 Unrealized foreign exchange — 100 Other, net 69 63 Deferred tax assets 33,499 35,732 Prepaid expenses (863 ) (820 ) Other, net (55 ) — Deferred tax liabilities (918 ) (820 ) Net deferred tax assets before valuation allowance 32,581 34,912 Less: valuation allowance (32,581 ) (34,912 ) Net deferred tax liabilities $ — $ — The Company recorded a valuation allowance during the years ended July 31, 2017 and 2016 equal to domestic and certain foreign net deferred tax assets. The Company believes that the valuation allowance is necessary as it is not more likely than not that the deferred tax assets will be realized in the foreseeable future based on positive and negative evidence available at this time. This conclusion was reached because of uncertainties relating to future taxable income, in terms of both its timing and its sufficiency, which would enable the Company to realize the deferred tax assets. For fiscal year 2017 and 2016 the change in the valuation allowance was $2.3 million and $14.7 million, respectively. As of July 31, 2017, the Company had U.S. federal net operating loss carryforwards of approximately $56.2 million. The U.S. federal tax loss carryforwards, if not fully utilized, expire between 2030 and 2035. Utilization is dependent on generating sufficient taxable income prior to expiration of the tax loss carryforwards. In addition, the Company has research and development tax credit carryforwards of approximately $1.1 million which expire between 2025 and 2037 and $1.1 million of alternative minimum tax credits which have an indefinite carryforward period. As of July 31, 2017, the Company had foreign loss carryforwards of approximately $9.3 million. The components of income (loss) before income taxes consisted of the following for the years ended July 31: 2017 2016 2015 United States operations $ (130 ) $ 48,847 $ (615 ) International operations (2,292 ) (2,332 ) (1,677 ) Income (loss) before taxes $ (2,422 ) $ 46,515 $ (2,292 ) The (provision) benefit for income taxes was at rates different from U.S. federal statutory rates for the following reasons for the years ended July 31: 2017 2016 2015 Federal statutory rate 34.0 % (34.0 )% 34.0 % Penalties and other expenses not deductible for income tax return purposes (14.5 ) (1.1 ) (18.6 ) State income taxes, net of benefit of federal tax deduction (2.1 ) (0.4 ) (0.5 ) Change in valuation allowance 64.0 32.9 (15.2 ) State tax law change (82.8 ) — — Other (2.0 ) — 0.6 (3.4 )% (2.6 )% 0.3 % U.S. federal income taxes have not been provided on approximately $87 of undistributed earnings at the Company’s foreign subsidiaries at July 31, 2017, because it is the Company’s intent to keep the earnings reinvested. As of July 31, 2017, the Company has no liabilities for uncertain tax positions. It is the Company’s policy to record interest and penalties as a component of tax expense. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and several foreign jurisdictions.

Loan Payable

Loan Payable	12 Months Ended
	Jul. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 - Loan Payable In June 2013, the Company entered into a secured Revolving Loan and Security Agreement (the “Credit Agreement”) among the Company and certain of its subsidiaries, with Enzo Therapeutics as a guarantor, and MidCap Financial LLC. (formerly Healthcare Finance Group, LLC). The Credit Agreement, which expired in December 2016, provided for borrowings against eligible US receivables, as defined, of the Clinical Lab and Life Science segments up to $8.0 million at defined eligibility percentages and provided for additional borrowings of $4.0 million for increased eligible assets. Debt issuance costs of $281 were amortized over the life of the Credit Agreement. The balance of unamortized debt issuance cost was zero and $28 at July 31, 2017 and 2016, respectively, and was included in prepaid expenses. The nominal interest rate for the four month period the loan was outstanding during fiscal year 2017 and year ended July 31, 2016 was 5.25%. The effective interest rate for the credit agreement was 14.3% for the four month period the loan was outstanding in fiscal 2017 and 11.4% for the fiscal year ended July 31, 2016. The Credit Agreement expired and was repaid in full on December 7, 2016.

Accrued Liabilities, Other Curr

Accrued Liabilities, Other Current Liabilities and Other Liabilities	12 Months Ended
	Jul. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 8 - Accrued Liabilities, Other Current Liabilities and Other Liabilities At July 31 accrued liabilities consist of: 2017 2016 Payroll, benefits, severance and commissions $ 4,092 $ 3,956 Legal 442 954 Professional fees 599 503 Research and development 143 300 Other 1,444 2,498 $ 6,720 $ 8,211 Self-Insured Medical Plan The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of July 31, 2017 and 2016, the Company has established a reserve of $0.3 million, which is included in accrued liabilities, for claims that have been reported but not paid and incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Other liabilities

Other liabilities	12 Months Ended
	Jul. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	Note 9 - Other liabilities At July 31 Other liabilities consist of: 2017 2016 Accrued legal settlement – see Note 14 $ 410 $ 800 Capital lease obligation 551 794 Installment loans 22 105 $ 983 $ 1,699 The capital lease obligation and Installment loans are for machinery and equipment used in the Clinical Labs segment. Amortization of the assets recorded under the capital lease is included in depreciation expense. At July 31, 2017, the accumulated amortization on the capital lease was $517 and the imputed interest rate ranges from 4.25% to 9.5%. Future minimum lease and loan payments are as follows: Capital lease Installment loans 2018 $ 209 $ 122 2019 258 24 2020 250 — 2021 165 — Total payments 882 146 Less: interest (122 ) (2 ) Total net of interest 760 144 Less: current portion (209 ) (122 ) Other liabilities - net $ 551 $ 22 The weighted average interest rate on our short term borrowings during fiscal 2017 and 2016 was 7.5% and 8.0%, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jul. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 10 - Stockholders’ equity Controlled Equity Offering The Company has a Controlled Equity Offering SM On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017. For the years ended July 31, 2017 and 2016, the Company did not sell any shares of common stock under the Sales Agreement. Common stock In fiscal 2017, the Company issued 91,541 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $724 for the match representing the fair value of the shares at the date of issuance. In fiscal 2016, the Company issued 160,352 shares of common stock for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $709 for the match representing the fair value of the shares at the date of issuance. In fiscal 2015, the Company issued 214,984 shares of common for its employees’ 401(k) matching contributions obligation. The Company recorded an expense of $662 for the match, representing the fair value of the shares at the date of issuance. Incentive stock plans The Company has an incentive stock option and restricted (non-vested) stock award plan (the “2005 Plan”), under which the Company could grant options and restricted stock (non-vested) awards for up to 1,000,000 common shares under the 2005 Plan. No additional awards may be granted under the 2005 Plan. On January 14, 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired. As of July 31, 2017, there were approximately 350,000 shares available for grant under the 2011 Plan. The Company estimates the fair value of each stock option award on the measurement date using a Black-Scholes option pricing model. The fair value of awards is amortized to expense on a straight line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, primarily time elapsed. Options granted pursuant to the plans may be either incentive stock options or non-statutory options The 2011 Plan provides for the issuance of stock options, restricted stock and restricted stock unit awards which generally vest over a two to four year period. A summary of the activity pursuant to the Company’s stock option plans for the years ended July 31, 2017, 2016, and 2015 is as follows: 2017 2016 2015 Options Weighted - Options Weighted - Options Weighted - Outstanding at beginning of year 1,808,875 $ 3.43 1,358,104 $ 3.04 1,155,910 $ 5.03 New Grants 496,996 $ 7.07 490,473 $ 4.48 383,873 $ 3.55 Exercised (141,876 ) $ 3.19 (33,702 ) $ 2.81 — $ — Expired (33,000 ) $ 5.29 (6,000 ) $ 3.61 (181,679 ) $ 16.84 Outstanding at end of year 2,130,995 $ 4.26 1,808,875 $ 3.43 1,358,104 $ 3.04 Exercisable at end of year 1,388,475 $ 3.27 1,094,794 $ 2.95 782,688 $ 2.88 Weighted average fair value of $ 2.43 $ 1.58 $ 1.36 The intrinsic value of stock option awards that vested during the fiscal year represents the value of the Company’s closing stock price on the last trading day of the fiscal year in excess of the exercise price multiplied by the number of options that vested. Total intrinsic value of options that vested and were exercisable during the fiscal years ended July 31, 2017, 2016, and 2015 was $10,530, $4,399 and $97, respectively. The intrinsic value of options outstanding at July 31, 2017, 2016, and 2015 was $14,510, $6,451 and $154, respectively. The intrinsic value of the options exercised in fiscal 2017 and 2016 was $1,388 and $64, respectively. On January 5, 2017, the Company awarded 264,896 options to the board of directors and senior officers with an exercise price of $7.07 and a five-year term, which vest annually over two years. The fair value of the options granted was $2.40 per share. The assumption used to fair value these options were as follow: expected life of 3.25 years, expected volatility 46.28%, a risk free interest rate of 1.48% and no dividend yield. As of July 31, 2017 none of these options were vested. On January 5, 2017, the Company also awarded 229,100 options to senior management and employees with an exercise price of $7.07 and a five-year term, which vest annually over three years. The fair value of the options granted was $2.48 per share. The assumption used to fair value these options were as follows: expected life of 3.50 years, expected volatility 45.85%, a risk free interest rate of 1.54% and no dividend yield. As of July 31, 2017 none of these options were vested. On March 14, 2016, the Company awarded 110,000 options to senior officers with an exercise price of $4.35 and a five-year term, which vest annually over two years. The fair value of the options granted was $1.46 per share. The assumption used to fair value these options were as follow: expected life of 3.25 years, expected volatility 46.13%, a risk free interest rate of 1.19% and no dividend yield. As of July 31, 2017, approximately 55,000 of these options were vested. On March 14, 2016, the Company also awarded 191,600 options to senior management and employees with an exercise price of $4.35 and a five-year term, which vest annually over three years. The fair value of the options granted was $1.57 per share. The assumption used to fair value these options were as follow: expected life of 3.5 years, expected volatility 48.14%, a risk free interest rate of 1.24% and no dividend yield. As of July 31, 2017, approximately 61,366 of these options were vested and 6,167 forfeited. On June 16, 2016, the Company awarded 2,000 options to an employee with an exercise price of $5.61 per share and a five-year term, which vest annually over two years. The fair value of the options granted was $1.88 per share. The assumption used to fair value these options were as follows: expected life of 3.25 years, expected volatility 46.64%, a risk free interest rate of 0.846% and no dividend yield. As of July 31, 2017, approximately 1,000 of these options were vested. On January 6, 2016, the Company awarded 189,873 options to the board of directors with an exercise price of $4.66 and a five-year term, which vest annually over two years. The fair value of the options granted was $1.65 per share. The assumption used to fair value these options were as follow: expected life of 3.25 years, expected volatility 48.6%, a risk free interest rate of 1.31% and no dividend yield. As of July 31, 2017, approximately 126,582 of these options were vested. On January 21, 2015, the Company awarded 293,373 options to two senior officers and the board of directors with an exercise price of $3.40 and a five-year term, which vest annually over two years. The fair value of the options granted was $1.27 per share. The assumptions used to fair value these option awards were as follows: expected life of 3.25 years, expected volatility 52.25%, a risk free interest rate of 0.93% and no dividend yield. As of July 31, 2017, all of these options were vested. Further on January 21, 2015, the Company awarded 40,000 options to executive officers with an exercise price of $3.40 and a five-year term, which vest annually over three years. The fair value of the options granted was $1.39 per share. The assumptions used to fair value these option awards were as follows: expected life of 3.5 years, expected volatility 55.63%, a risk free interest rate of 1.00% and no dividend yield. As of July 31, 2017, approximately 23,334 of these options were vested and 5,000 were forfeited. The following table summarizes information for stock options outstanding at July 31, 2017: Options outstanding and exercisable Range of Exercise prices Shares Weighted-Average Weighted-Average $2.53 - $4.35 1,425,460 1.13 $ 3.25 $4.66 - $7.07 705,535 1.35 $ 6.31 2,130,995 Restricted Stock Awards During fiscal 2017, 2016 and 2015, the compensation committee of the Company’s board of directors approved grants of restricted stock and restricted stock unit awards (the “Awards”) to certain officers and certain employees under the 2011 or 2005 Plans. The Awards vest upon the recipient’s continued employment service rateably over either two, three or four years. Share-based compensation expense is based on the fair value of the award as measured on the grant date and is recorded over the vesting period on a straight-line basis. The Awards will be forfeited if the recipient ceases to be employed by the Company, as defined in the Plans’ terms. The Awards settle in shares of the Company’s common stock on a one-for-one basis. The following table summarizes the activity pursuant to restricted stock awards for the years ended July 31, 2017 2016 2015 Awards Weighted - Awards Weighted - Awards Weighted - Outstanding at beginning of year 8,501 $ 4.13 21,501 $ 8.84 42,502 $ 5.74 Awarded 4,250 $ 6.95 — $ — 4,250 $ 4.75 Vested (5,140 ) $ (4.10 ) (11,500 ) $ (2.83 ) (19,418 ) $ (2.83 ) Forfeited (175 ) $ (2.14 ) (1,500 ) $ (2.86 ) (5,833 ) $ (3.22 ) Outstanding (non-vested) at end of year 7,436 $ 4.45 8,501 $ 4.13 21,501 $ 8.84 Weighted average market value of awards granted during year $ 6.95 $ — $ 4.75 The fair value of the awards that vested during the years ended July 31, 2017, 2016 and 2015 was $44, $46 and $79, respectively.

Employee benefit plan

Employee benefit plan	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 11 - Employee benefit plan The Company has a qualified Salary Reduction Profit Sharing Plan (the “Plan”) for eligible U.S. employees under Section 401(k) of the Internal Revenue Code. The Plan provides for voluntary employee contributions through salary reduction and voluntary employer contributions at the discretion of the Company. For the years ended July 31, 2017, 2016, and 2015, the Company authorized employer matched contributions of 50% of the employees’ contribution up to 10% of the employees’ compensation, payable in Enzo Biochem, Inc. common stock. The share-based 401(k) employer matched contribution was approximately $724, $709, and $662 in fiscal years 2017, 2016, and 2015, respectively. As of July 31, 2017, 2016 and 2015 the Company accrued a total of $412, $413 and $387 in 401(K) matching contributions within the Accrued liabilities account. The Company’s Swiss operations provide a pension plan named the Enzo Life Sciences (ELS) AG Vertrag - Nr. 2/401144, (the “Swiss Plan”) under the Swiss government’s social security system for Swiss employees. The current required minimum saving contribution is 13% for employees over age 25 and minimum annual investment return is 1.00%. Employees are required to contribute based on a formula and the Company’s Swiss operations make contributions of at least 50% of the employee contribution. The status of the Swiss Plan, which is substantially funded as of December 31, 2016, the latest plan year end, is as follows: As of December 31, 2016 2015 2014 Total Assets $ 2,184 $ 2,149 $ 2,132 Accumulated Benefit Obligation $ 2,432 $ 2,397 $ 2,421 Funded status 90 % 90 % 88 % Fiscal Year ended July 31, 2016 2015 2014 Contributions $ 224 $ 224 $ 279 The Swiss Plan’s contract expires December 31, 2019 and currently the Company has no plans to change the current funding or plan design. No events have occurred that would impact the Swiss Plan status.

Royalty and other income

Royalty and other income	12 Months Ended
	Jul. 31, 2017
Royalty And Other Income [Abstract]
Royalty And Other Income [Text Block]	Note 12 - Royalty and other income The Company has a license agreement with Qiagen that began in 2005, whereby the Company earns quarterly running royalties on the net sales of Qiagen products subject to the license until the expiration of the patent on April 24, 2018. During the years ended July 31, 2017, 2016 and 2015, the Company recorded royalty income under the agreement of approximately $1,205, $1,521 and $2,495 respectively, which is included in the Life Sciences segment.

Commitments

Commitments	12 Months Ended
	Jul. 31, 2017
Disclosure Text Block Supplement [Abstract]
Commitments Disclosure [Text Block]	Note 13 - Commitments Leases The Company leases equipment, office and laboratory space under several non-cancellable operating leases that expire between September 2017 and June 2028. Certain leases include renewal options and rent escalation clauses. An entity owned by certain executive officers/directors of the Company owns the building that the Company leases as its main facility for clinical laboratory operations and certain research operations. In addition to the minimum annual rentals of space, the lease is subject to annual increases, based on the consumer price index. Annual increases are limited to 3% per year. Rent expense for this lease, inclusive of real estate taxes, approximated $1,752, $1,704, and $1,623 (net of real estate tax abatement received of $61 for years 2016 and 2015) during fiscal years 2017, 2016 and 2015, respectively. Total rent expense incurred by the Company during fiscal 2017, 2016 and 2015 for all its facilities was approximately $4,658, $4,572 and $4,504, respectively. Minimum future annual rentals under all non-cancellable operating leases, net of sublease rental income of $323, as of July 31, 2017, are as follows: Years ended July 31, 2018 $ 6,713 2019 6,474 2020 4,459 2021 3,146 2022 2,738 Thereafter 8,109 $ 31,639 Employment Agreements The Company has employment agreements with certain officers that are cancellable at any time but provide for severance pay in the event an officer is terminated by the Company without cause, as defined in the agreements. Unless cancelled earlier or with notice as defined, the agreement automatically renews for two years. Aggregate minimum compensation commitments, exclusive of any severance provisions as of July 31, 2017 is $2,498.

Contingencies

Contingencies	12 Months Ended
	Jul. 31, 2017
Loss Contingency [Abstract]
Contingencies Disclosure [Text Block]	Note 14 – Contingencies June 2004, the Company and Enzo Life Sciences, Inc., filed suit in the United States District Court for the District of Connecticut against Applera Corporation and its wholly-owned subsidiary Tropix, Inc., which became Life Technologies, Inc. and was acquired by Thermo Fisher Scientific, Inc. (NYSE:TMO) on February 2014. The complaint alleged infringement of six patents relating to DNA sequencing systems, labeled nucleotide products, and other technology. Yale University is the owner of four of the patents and the Company is the exclusive licensee. These four patents are commonly referred to as the “Ward” patents. In November 2012, a jury in New Haven found that one of these patents (United States Patent No. 5,449,667) was infringed and not proven invalid. The jury awarded $48.5 million for this infringement. In January 2014, the judge awarded prejudgment interest of approximately $12.5 million and additional post-interest on the full amount was also being awarded starting November 2012 until the total award is satisfied. The final award to the Company could have been reduced or subject to possible claims from third parties. In March 2015, the Court of Appeals for the Federal Circuit vacated that judgment in a decision remanding the matter to the district court for further proceedings. On February 22 2016, the Connecticut District Court granted Applera’s motion for summary judgment of non-infringement. The Company appealed that decision. On August 2, 2017, the Court of Appeals for the Federal Circuit affirmed a judgment of the United States District Court for the District of Connecticut, on February 22, 2016. The lower court found that Applera Corp. (now part of Thermo-Fischer) had not infringed our patent and the Federal Circuit affirmed that finding. We are considering our options. There can be no assurance that we will be successful in this litigation. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. As of August 1, 2014 the Company was engaged in litigation in the United States District Court for the Southern District of New York against Roche Diagnostic GmbH and its related company Roche Molecular Systems, Inc. (“Roche”), as declaratory judgment defendant. This case was commenced in May 2004. Roche seeks a declaratory judgment of non-breach of contract and patent invalidity against the Company. Roche has also asserted tort claims against the Company. The Company has asserted breach of contract and patent infringement causes of action against Roche. There has been extensive discovery in the case. In 2011, Roche moved for summary judgment of non-infringement regarding the Company’s patent claims. In 2012, the motion was granted in part and denied in part. In December 2012, Roche moved for summary judgment on the Company’s non-patent claims. Additional discovery was taken and the Company responded to the motions in May 2013. In December 2013, the Court granted in part and denied in part Roche’s summary judgment motion. In October 2014, the Court ordered that damages discovery concerning the Company’s remaining contract and patent claims and Roche’s claims should be completed by the end of January 2015, and expert discovery should be completed following the Court’s not-yet-issued claim construction ruling concerning the Company’s patent infringement claim against Roche. Roche dropped its tort claims during damages discovery. In April 2015, the Court heard oral argument on claim construction issues. In May 2015, Roche and the Company jointly moved the Court to extend the schedule for damages discovery until the end of May 2015, and the Court granted that motion. The parties are waiting for the Courts’ ruling on claim construction. The Company and Enzo Life Sciences intend to vigorously press their remaining claims and contest the claims against them. In September 2014, the Company and the U.S. Department of Justice reached a settlement agreement to resolve an investigation focused primarily on an alleged failure to collect diagnosis codes from physicians who ordered tests through Enzo Clinical Labs. During fiscal year 2014, the Company recorded a charge of $2.0 million in the statement of operations under legal settlements, net within the Clinical Labs segment. The settlement amount is being paid with interest over a five-year period. During fiscal year 2016, the Company accrued an additional $1.5 million, due to the Company’s achievement of certain financial milestones. As of July31, 2017, the total liability for this settlement is $0.8 million, of which $0.4 million is included in other current liabilities and $0.4 million included in other liabilities. In June 2014, the Company, as plaintiff finalized and executed a settlement agreement with PerkinElmer, Inc., and PerkinElmer Health Sciences, Inc. (formerly known as PerkinElmer Life Sciences, Inc.) (together, “PerkinElmer”), with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817. PerkinElmer paid $7.0 million in escrow pursuant to the agreement because of a former attorney’s charging lien for fees allegedly owed for past services rendered to the Company. In December 2015, the Company entered into a Settlement Agreement with the former attorney pursuant to which the Company and the former attorney resolved their respective claims against each other. In January 2016, the Company received a total of approximately $7.0 million from the escrow referred to above in accordance with the terms of the Settlement Agreement which was included in the statement of operations under Legal settlements, net within the Life Science segment in the 2016 period. In October 2015, the Company reached and finalized a settlement with Affymetrix, Inc. in the amount of $6.8 million, net in a patent infringement action brought by the Company. In January 2016, the Company reached and finalized a settlement agreement with Agilent Technologies, Inc. in the amount of $6.1 million, net in a patent infringement action brought by the Company. Both cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements were included in the statement of operations during the 2016 fiscal period under Legal settlements, net within the Life Science segment. In May 2016, the Company reached and finalized a settlement with Life Technologies Corporation in the amount of $24.3 million, net in an infringement action brought by the Company regarding its US Patents No. 6,992,180 and 7,064,197. In July 2016, the Company reached and finalized a settlement with Illumina, Inc., in the amount of $14.5 million, net in an infringement action brought by the Company regarding US Patent No. 7,064,197. These cases were originally brought by the Company in the United States District Court for the District of Delaware. The settlements are included in the statement of operations under Legal settlements, net within the Life Science segment for the 2016 period. As of July 31, 2017, there are seven pending cases originally brought by the Company in the United States District Court for the District of Delaware (“the Court”) alleging patent infringement against various companies. On June 28, 2017, the Court issued an opinion in the Gen-Probe case, granting Gen-Probe’s motion for summary judgment that the asserted claims of the ’180 patent are invalid for nonenablement. The Court entered final judgment of invalidity of the asserted claims of the ‘180 patent on July 19, 2017 in the Gen-Probe and Hologic cases. The Court entered partial final judgment of invalidity of the asserted claims of the ‘180 patent and stayed the remainder of the cases in the Becton Dickinson and Roche cases on July 31, 2017 and August 2, 2017, respectively. The Company has filed notices of appeal in each of the Gen-Probe, Hologic, Becton Dickinson, and Roche cases, which have been docketed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). In the Abbott case, the parties agreed that the Court’s summary judgment ruling in the Gen-Probe case invalidated all of the ’180 patent claims asserted against the Abbott Defendants. On August 15, 2017, the Court granted Abbott’s motion for summary judgment that the asserted claims of the ’405 patent are invalid for nonenablement. On September 1, 2017, the Court entered final judgement of invalidity of the asserted claims of the ‘180 and ‘405 patents for nonenablement. Enzo subsequently filed a notice of appeal on September 14, 2017. The Federal Circuit docketed the appeal on September 15, 2017. The Federal Circuit has consolidated the appeals from the Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche litigations (“Consolidated Appeals”) and set November 28, 2017 as the deadline for Enzo to file its opening brief in the Consolidated Appeals. We disagree with the Court’s invalidity decisions regarding the ‘180 and ‘405 patents in the pending cases and continue to explore options for review of those decisions. In the other two cases involving Hologic, one of the cases is stayed, while the other case is proceeding under the Court’s scheduling order with fact and expert discovery deadlines through September 2018, a summary judgment hearing date in February 2019, and a trial date in May 2019. The Company currently uses one third party reference lab for certain clinical laboratory services we provide which represents 18% of the consolidated purchases for the year ended July 31, 2017. Although there are a limited number of reference labs available for those clinical laboratory services, we believe that these other references labs could provide us with such testing results on comparable terms. A change in reference labs, however, could cause a delay in obtaining and reporting those test results and a possible loss of services revenues, which would affect operating results adversely. There can be no assurance that the Company will be successful in these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations

Segment reporting

Segment reporting	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 15 - Segment reporting The Company has three reportable segments: Life Sciences, Clinical Labs and Therapeutics. The Company’s Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Labs segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. Legal fee expense incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal fee expense specific to other segments’ activities have been allocated to those segments. Legal settlements, net, represent activities for which royalties would have been received in the Company’s Life Sciences segment and expenses related to an investigation within the Clinical Labs segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Year ended July 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 77,407 — — — $ 77,407 Product revenues — $ 29,192 — — 29,192 Royalty and license fee income — 1,205 — — 1,205 Total revenues 77,407 30,397 — — 107,804 Operating costs and expenses: Cost of clinical laboratory services 45,400 — — — 45,400 Cost of product revenues — 14,078 — — 14,078 Research and development — 2,311 $ 617 — 2,928 Selling, general and administrative 24,465 11,232 — $ 8,313 44,010 Provision for uncollectible accounts receivable 2,718 57 — — 2,775 Legal fee expense 146 79 — 1,454 1,679 Total operating costs and expenses 72,729 27,757 617 9,767 110,870 Operating income (loss) 4,678 2,640 (617 ) (9,767 ) (3,066 ) Other income (expense) Interest (112 ) 46 — 450 384 Other 137 (60 ) — 48 125 Foreign exchange gain — 135 — — 135 Income (loss) before taxes $ 4,703 $ 2,761 $ (617 ) $ (9,269 ) $ (2,422 ) Depreciation and amortization included above $ 1,586 $ 1,913 $ — $ 99 $ 3,598 Share-based compensation included in above: Cost of clinical laboratory services $ 6 $ — $ — $ — $ 6 Selling, general and administrative 111 74 — $ 640 825 Total $ 117 $ 74 $ — $ 640 $ 831 Capital expenditures $ 1,363 $ 390 $ — $ — $ 1,753 The following financial information represents the operating results of the reportable segments of the Company: Year ended July 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 70,915 — — — $ 70,915 Product revenues — $ 30,337 — — 30,337 Royalty and license fee income — 1,521 — — 1,521 Total revenues 70,915 31,858 — — 102,773 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 42,859 — — — 42,859 Cost of product revenues — 14,331 — — 14,331 Research and development — 2,720 $ 804 — 3,524 Selling, general and administrative 22,882 11,761 — $ 8,943 43,586 Provision for uncollectible accounts receivable 2,375 (39 ) — — 2,336 Legal fee expense 134 11 — 6,239 6,384 Legal settlements, net 1,500 (58,750 ) — — (57,250 ) Total operating costs, expenses and legal settlements, net 69,750 (29,966 ) 804 15,182 55,770 Operating income (loss) 1,165 61,824 (804 ) (15,182 ) 47,003 Other income (expense) Interest (105 ) 47 — (78 ) (136 ) Other 10 38 — 74 122 Foreign exchange gain — (474 ) — — (474 ) Income (loss) before taxes $ 1,070 $ 61,435 $ (804 ) $ (15,186 ) $ 46,515 Depreciation and amortization included above $ 1,676 $ 2,091 $ — $ 73 $ 3,840 Share-based compensation included in above: Cost of clinical laboratory services $ 6 $ — $ — $ — $ 6 Selling, general and administrative 51 30 — $ 438 519 Total $ 57 $ 30 $ — $ 438 $ 525 Capital expenditures $ 1,216 $ 314 $ — $ — $ 1,530 The following financial information represents the operating results of the reportable segments of the Company: Year ended July 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 63,414 — — — $ 63,414 Product revenues — $ 31,690 — — 31,690 Royalty and license fee income — 2,495 — — 2,495 Total revenues 63,414 34,185 — — 97,599 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 39,589 — — — 39,589 Cost of product revenues — 15,183 — — 15,183 Research and development — 2,608 $ 742 — 3,350 Selling, general and administrative 20,666 12,168 — $ 8,235 41,069 Provision for uncollectible accounts receivable 2,418 (134 ) — — 2,284 Legal fee expense 196 (67 ) — 8,659 8,788 Legal settlements, net — (11,458 ) — — (11,458 ) Total operating costs, expenses and legal settlements, net 62,869 18,300 742 16,894 98,805 Operating (loss) income 545 15,885 (742 ) (16,894 ) (1,206 ) Other income (expense) Interest (86 ) 10 — (169 ) (245 ) Other 28 9 — 58 95 Foreign exchange gain — (936 ) — — (936 ) (Loss) income before income taxes $ 487 $ 14,968 $ (742 ) $ (17,005 ) $ (2,292 ) Depreciation and amortization included above $ 1,443 $ 2,254 $ 3 $ 89 $ 3,789 Share-based compensation included in above: Cost of clinical laboratory services $ 5 $ — — — $ 5 Research and development — 2 — — 2 Selling, general and administrative 43 15 — $ 364 422 Total $ 48 $ 17 — $ 364 $ 429 Capital expenditures $ 1,557 $ 226 — — $ 1,783 Geographic financial information is as follows: Net sales to unaffiliated customers: 2017 2016 2015 United States $ 99,469 $ 94,016 $ 87,875 Switzerland 2,371 2,709 3,131 United Kingdom 1,673 1,730 1,904 Other international countries 4,291 4,318 4,689 Total $ 107,804 $ 102,773 $ 97,599 Long-lived assets at July 31, 2017 2016 United States $ 17,241 $ 18,730 Switzerland 649 917 United Kingdom 185 244 Other international countries 173 197 Total $ 18,248 $ 20,088 The Company’s reportable segments are determined based on the services they perform, the products they sell, and the royalties and license fee income they earn, not on the geographic area in which they operate. The Company’s Clinical Labs segment operates 100% in the United States with all revenue derived there. The Life Sciences segment earns product revenue both in the United States and foreign countries and royalty and license fee income in the United States. The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries: 2017 2016 2015 United States $ 22,062 $ 23,102 $ 24,461 Foreign countries 8,335 8,756 9,724 $ 30,397 $ 31,858 $ 34,185

Summary of Selected Quarterly F

Summary of Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Jul. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Text Block]	Note 16 - Summary of Selected Quarterly Financial Data (unaudited) The following table contains statement of operations information for each quarter of the years ended July 31, 2017 and 2016. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair presentation of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. Unaudited quarterly financial data for fiscal 2016 and 2015 is summarized as follows: Quarter Ended Fiscal 2017 October 31, January 31, April 30, July 31, Total revenues $ 26,284 $ 26,260 $ 27,089 $ 28,171 Gross profit 12,079 11,688 12,173 12,386 Income (loss) before income taxes (1,454 ) (1,000 ) (39 ) 71 Net income (loss) (1,474 ) (1,053 ) (71 ) 94 Basic income (loss) per common share $ (0.03 ) $ (0.02 ) $ (0.00 ) $ 0.00 Diluted income (loss) per common share (0.03 ) (0.02 ) (0.00 ) 0.00 Quarter Ended Fiscal 2016 October 31, January 31, April 30, July 31, Total revenues $ 25,177 $ 24,560 $ 26,433 $ 26,603 Gross profit 11,234 10,819 11,445 12,085 Income (loss) before income taxes 4,521 7,039 (2,113 ) 37,068 Net income (loss) 4,434 6,832 (2,115 ) 36,135 Basic income (loss) per common share $ 0.10 $ 0.15 $ (0.05 ) $ 0.78 Diluted income (loss) per common share 0.10 0.15 (0.05 ) 0.77

SCHEDULE II VALUATION AND QUALI

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Jul. 31, 2017
Valuation and Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	ENZO BIOCHEM, INC VALUATION AND QUALIFYING ACCOUNTS Years ended July 31, 2017, 2016 and 2015 (in thousands) Year ended Description Balance at Charged Charged Deductions Balance at 2017 Allowance for doubtful accounts receivable 3,517 2,775 2,716 (1) 3,576 2016 Allowance for doubtful accounts receivable 1,786 2,336 605 (1) 3,517 2015 Allowance for doubtful accounts receivable 2,142 2,284 2,640 (1) 1,786 2017 Deferred tax valuation allowance 34,912 (2,179 ) 32,733 2016 Deferred tax valuation allowance 49,658 (14,746 ) 34,912 2015 Deferred tax valuation allowance 49,465 193 49,658 (1) Write-off of uncollectible accounts receivable.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Nature of Business [Policy Text Block]	Nature of business Enzo Biochem, Inc. (the “Company”) is an integrated life science and biotechnology company engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company is conducting research and development activities in the development of therapeutic products based on the Company’s technology platform of genetic modulation and immune modulation. The Company also operates a clinical laboratory that offers and provides molecular and esoteric diagnostic medical testing services in the New York and New Jersey medical communities. The Company operates in three segments (see Note 15).
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiaries, Enzo Clinical Labs, Inc., Enzo Life Sciences, Inc. (and its wholly-owned foreign subsidiaries), Enzo Therapeutics, Inc. and Enzo Realty LLC (“Realty”). All intercompany transactions and balances have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation/Transactions The Company has determined that the functional currency for its foreign subsidiaries is the local currency. For financial reporting purposes, assets and liabilities denominated in foreign currencies are translated at current exchange rates and profit and loss accounts are translated at weighted average exchange rates. Resulting translation gains and losses are included as a separate component of stockholders’ equity as accumulated other comprehensive income or loss. Gains or losses resulting from transactions entered into in other than the functional currency are recorded as foreign exchange gains and losses in the consolidated statements of operations.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents Cash and cash equivalents consist of demand deposits with banks and highly liquid money market funds. At July 31, 2017 and 2016, the Company had cash and cash equivalents in foreign bank accounts of $0.5 million.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Values of Financial Instruments The recorded amounts of the Company’s cash and equivalents, receivables, loan payable, accounts payable and accrued liabilities approximate their fair values principally because of the short-term nature of these items.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and accounts receivable. The Company believes the fair value of the aforementioned financial instruments approximates the cost due to the immediate or short-term nature of these items. Concentration of credit risk with respect to the Company’s Life Sciences segment is mitigated by the diversity of the Company’s clients and their dispersion across many different geographic regions. To reduce risk, the Company routinely assesses the financial strength of these customers and, consequently, believes that its accounts receivable credit exposure with respect to these customers is limited. The Company believes that the concentration of credit risk with respect to the Clinical Labs accounts receivable is mitigated by the diversity of third party payers that insure individuals. To reduce risk, the Company routinely assesses the financial strength of these payers and, consequently, believes that its accounts receivable credit risk exposure, with respect to these payers, is limited. While the Company also has receivables due from the Federal Medicare program, the Company does not believe that these receivables represent a credit risk since the Medicare program is funded by the federal government and payment is primarily dependent on our submitting the appropriate documentation.
Accrual For Self-Funded Medical [Policy Text Block]	Accrual for Self-Funded Medical Accruals for self-funded medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition - Product revenues Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectability is reasonably assured.
Revenue Recognition, Services, Royalty Fees [Policy Text Block]	Royalties Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues.
Clinical Laboratory Services [Policy Text Block]	Clinical laboratory services Revenues from the Clinical Labs segment are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected reimbursable settlements from such payers. The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: Years Ended July 31, 2017 2016 2015 Revenue category Amount % Amount % Amount % Third-party payers $ 43,059 56 $ 34,454 49 $ 30,685 49 Patient self-pay 11,380 15 14,744 21 11,028 17 Medicare 12,705 16 11,392 16 11,981 19 HMO’s 10,263 13 10,325 14 9,720 15 Total $ 77,407 100 % $ 70,915 100 % $ 63,414 100 % The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs (See Note 14). Other than the Medicare program, one provider whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 39%, 30% and 28% of the Clinical Labs segment net revenue for the years ended July 31, 2017, 2016 and 2015 respectively.
Contractual Adjustments and Third Party Settlements, Policy [Policy Text Block]	Contractual Adjustment The Company’s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue based on gross billing rates to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule the Company sets for all third-party payers, including Medicare, HMO’s and managed care providers. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors which include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements and 3) the growth of in-network provider arrangements and managed care plans specific to our Company. During the years ended July 31, 2017, 2016 and 2015, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were approximately 84%, 84% and 85%, respectively, of gross billings.
Accounts Receivable And Allowance For Doubtful Accounts [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue. For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and reduces the allowance in future accounting periods based on write-offs during those periods. It bases the estimate for the allowance on the evaluation of historical experience of accounts going to collections and the net amounts not received. Accounts going to collection include the balances, after receipt of the approved settlements from third party payers, for the insufficient diagnosis information received from the ordering physician which results in denials of payment, and our estimate of the uncollected portion of receivables from self-payers, including deductibles and copayments, which are subject to credit risk and patients’ ability to pay. The Company fully reserves through its contractual allowances amounts that have not been written off because the payer’s filing date deadline has not occurred or the collection process has not been exhausted. The Company adjusts the historical collection analysis for recoveries, if any, on an on-going basis. The Company’s ability to collect outstanding receivables from third-party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection issues and to assess the impact, if any, on the allowance estimates which involves judgment. The Company believes that the collectability of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount. The allowance for doubtful accounts as a percentage of total accounts receivable at July 31, 2017 and 2016 was 19.1% and 19.4% respectively. The Clinical Labs segment’s net receivables are detailed by billing category and as a percent to its total net receivables. At July 31, 2017 and 2016, approximately 75% and 71%, respectively, of the Company’s net accounts receivable relates to its Clinical Labs business, which operates in the New York and New Jersey medical communities. The Life Sciences segment’s accounts receivable includes royalties receivable of $0.4 million and $0.5 million, as of July 31, 2017 and 2016, respectively, due from QIAGEN Gaithersburg Inc. (“Qiagen”) (see Note 12). The following is a table of the Company’s net accounts receivable by segment. July 31, 2017 July 31, 2016 Net accounts receivable by segment Amount % Amount % Clinical Labs (by billing category) Third party payers $ 7,256 64 $ 5,861 57 Patient self-pay 1,591 14 1,676 16 Medicare 1,385 12 1,486 14 HMO’s 1,169 10 1,341 13 Total Clinical Labs 11,401 100 % 10,364 100 % Total Life Sciences 3,779 4,228 Total accounts receivable – net $ 15,180 $ 14,592 Changes in the Company’s allowance for doubtful accounts are as follows: July 31, 2017 July 31, 2016 Beginning balance $ 3,517 $ 1,786 Provision for doubtful accounts 2,775 2,336 Write-offs (2,716 ) (605 ) Ending balance $ 3,576 $ 3,517
Inventory, Policy [Policy Text Block]	Inventories The Company values inventory at the lower of cost (first-in, first-out) or net realizable value, which approximates market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.
Property, Plant and Equipment, Policy [Policy Text Block]	Property, plant and equipment Property, plant and equipment is stated at cost, and depreciated on the straight-line basis over the estimated useful lives of the various asset classes as follows: building and building improvements: 15-30 years, and laboratory machinery and equipment and office furniture and computer equipment which range from 3-10 years. Leasehold improvements are amortized over the term of the related leases or estimated useful lives of the assets, whichever is shorter.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Intangible Assets Goodwill represents the excess of the cost of an acquisition over the fair value of the net assets acquired. Intangible assets (exclusive of patents), arose primarily from acquisitions, and primarily consist of customer relationships, trademarks, licenses, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. Indefinite-lived intangibles are not amortized and are evaluated each reporting period to determine whether events and circumstances continue to support their having an indefinite life. Indefinite-lived intangibles found to no longer have an indefinite life are evaluated for impairment and are then amortized over their remaining useful life as finite-lived intangible assets. Patents represent capitalized legal costs incurred in pursuing patent applications. When such applications result in an issued patent, the related capitalized costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment testing for Goodwill and Long-Lived Assets The Company tests goodwill annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. In assessing goodwill for impairment, the Company has the option to first perform a qualitative assessment to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company is not required to perform any additional tests in assessing goodwill for impairment. However, if the Company concludes otherwise or elects not to perform the qualitative assessment, then it is required to perform the first step of a two-step quantitative impairment review process. The first step of the quantitative impairment test requires the identification of the reporting units and comparison of the fair value of each of these reporting units to their respective carrying amount. If the carrying amount of the reporting unit is less than its fair value, no impairment exists and the second step is not performed. If the carrying amount of the reporting unit is higher than its fair value, the second step must be performed to compute the amount of the goodwill impairment. In the second step, the impairment charge is the amount by which the carrying amount exceeds the reporting unit’s fair value, not to exceed the total amount of goodwill allocated to the reporting unit. The Company performed a quantitative assessment in 2017 and a qualitative assessment in 2016 and 2015, and concluded there were no goodwill impairments. The Company reviews the recoverability of the carrying value of long-lived assets (including intangible assets with finite lives) for impairment annually as of the first day of the fourth quarter, or more frequently if indicators of potential impairment exist. Should indicators of impairment exist, the carrying values of the assets are evaluated in relation to the operating performance and future undiscounted cash flows of the underlying business. The net book value of an asset is adjusted to fair value if its expected future undiscounted cash flow is less than its book value. There were no long-lived asset impairments in 2017, 2016 or 2015.
Comprehensive Loss [Policy Text Block]	Comprehensive income (loss) Comprehensive income (loss) consists of the Company’s consolidated net income (loss) and foreign currency translation adjustments. Foreign currency translation adjustments included in comprehensive income (loss) were not tax effected as investments in international affiliates are deemed to be permanent. Accumulated other comprehensive income is a separate component of stockholders’ equity and consists of the cumulative foreign currency translation adjustments.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Costs Shipping and handling costs associated with the distribution of finished goods to customers are recorded in cost of goods sold.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to expense as incurred.
Advertising Costs, Policy [Policy Text Block]	Advertising All costs associated with advertising are expensed as incurred. Advertising expense, included in selling, general and administrative expense, approximated $649, $601 and $556 for the years ended July 31, 2017, 2016 and 2015, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance when it is more likely than not that the benefits may not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At July 31, 2017, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company separately reports information about each operating segment that engages in business activities from which the segment may earn revenues and incur expenses, whose separate operating results are regularly reviewed by the chief operating decision maker regarding allocation of resources and performance assessment and which exceed specific quantitative thresholds related to revenue and profit or loss. The Company’s operating activities are reported in three segments (see Note 15).
Earnings Per Share, Policy [Policy Text Block]	Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Diluted weighted average shares outstanding for fiscal 2017 and 2015 do not include the potential common shares from stock options and unvested restricted stock because to do so would have been antidilutive and as such is the same as basic weighted average shares outstanding for 2017 and 2015. For fiscal 2016, approximately 449,000 weighted average stock options were included in the calculation of diluted weighted average shares outstanding. The number of potential common shares (“in the money options”) and unvested restricted stock excluded from the calculation of diluted weighted average shares outstanding for the years ended July 31, 2017, and 2015 was 961,000, and 403,000, respectively. For the years ended July 31, 2017, 2016 and 2015, the effect of approximately zero, 282,000 and 977,000 respectively, of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted weighted average shares outstanding because their effect would be anti-dilutive. The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: 2017 2016 2015 Net (loss) income $ (2,504 ) $ 45,286 $ (2,285 ) Weighted-average common shares outstanding - basic 46,350 46,153 45,355 Add: effect of dilutive stock options and restricted stock — 449 — Weighted-average common shares outstanding - diluted 46,350 46,602 45,355 Net (loss) income per share – basic $ (0.05 ) $ 0.98 $ (0.05 ) Net (loss) income per share – diluted $ (0.05 ) $ 0.97 $ (0.05 )
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation The Company records compensation expense associated with stock options and restricted stock based upon the fair value of stock based awards as measured at the grant date. The Company determines the award values of stock options using the Black Scholes option pricing model. The expense is recorded by amortizing the fair values on a straight-line basis over the vesting period, adjusted for forfeitures. For the years ended July 31, 2017, 2016 and 2015, share-based compensation expense relating to the fair value of stock options, restricted shares and restricted stock units was approximately $831, $525, and $429, respectively (see Note 10). No excess tax benefits were recognized for the year ended July 31, 2016, 2015 and 2014. The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: 2017 2016 2015 Cost of clinical laboratory services $ 6 $ 6 $ 5 Research and development — — 2 Selling, general and administrative 825 519 422 $ 831 $ 525 $ 429 As of July 31, 2017, there was $1,187 of total unrecognized compensation cost related to non-vested share-based payment arrangements granted under the Company’s incentive stock plans, which will be recognized over a weighted average remaining life of approximately seventeen months.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In November 2015, the FASB issued ASU 2015-17, Income Taxes – Balance Sheet Classification of Deferred Taxes In April 2015, the FASB issued ASU No. 2015-03 Interest – Imputation of Interest. In July 2015, the FASB issued ASU No. 2015-11, Simplifying the Measurement of Inventory (Topic 330). In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other – Simplifying the Test for Goodwill Impairment
Pronouncements Issued But Not Yet Adopted Policy	Pronouncements Issued but Not Yet Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers: Topic 606 In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02 – Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” In May 2017, the FASB issued ASU 2017-09, “ Compensation – Stock Compensation (Topic 708) Scope of Modification Accounting

Summary of significant accoun27

Summary of significant accounting policies (Tables)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Schedule Of Segment Revenue And Revenue Percentage [Table Text Block]	The following table summarizes the Clinical Lab segment’s net revenues and revenue percentages by revenue category: Years Ended July 31, 2017 2016 2015 Revenue category Amount % Amount % Amount % Third-party payers $ 43,059 56 $ 34,454 49 $ 30,685 49 Patient self-pay 11,380 15 14,744 21 11,028 17 Medicare 12,705 16 11,392 16 11,981 19 HMO’s 10,263 13 10,325 14 9,720 15 Total $ 77,407 100 % $ 70,915 100 % $ 63,414 100 %
Schedule Of Accounts Receivable By Segment [Table Text Block]	The following is a table of the Company’s net accounts receivable by segment. July 31, 2017 July 31, 2016 Net accounts receivable by segment Amount % Amount % Clinical Labs (by billing category) Third party payers $ 7,256 64 $ 5,861 57 Patient self-pay 1,591 14 1,676 16 Medicare 1,385 12 1,486 14 HMO’s 1,169 10 1,341 13 Total Clinical Labs 11,401 100 % 10,364 100 % Total Life Sciences 3,779 4,228 Total accounts receivable – net $ 15,180 $ 14,592
Schedule of Allowance for Doubtful Accounts Receivable [Table Text Block]	Changes in the Company’s allowance for doubtful accounts are as follows: July 31, 2017 July 31, 2016 Beginning balance $ 3,517 $ 1,786 Provision for doubtful accounts 2,775 2,336 Write-offs (2,716 ) (605 ) Ending balance $ 3,576 $ 3,517
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of basic and diluted net loss per share for the years ended July 31: 2017 2016 2015 Net (loss) income $ (2,504 ) $ 45,286 $ (2,285 ) Weighted-average common shares outstanding - basic 46,350 46,153 45,355 Add: effect of dilutive stock options and restricted stock — 449 — Weighted-average common shares outstanding - diluted 46,350 46,602 45,355 Net (loss) income per share – basic $ (0.05 ) $ 0.98 $ (0.05 ) Net (loss) income per share – diluted $ (0.05 ) $ 0.97 $ (0.05 )
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31: 2017 2016 2015 Cost of clinical laboratory services $ 6 $ 6 $ 5 Research and development — — 2 Selling, general and administrative 825 519 422 $ 831 $ 525 $ 429

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	12 Months Ended
	Jul. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences segment is as follows: Gross Accumulated Amortization Net July 31, 2015 $ 27,838 $ (21,683 ) $ 6,155 Amortization expense — (1,677 ) (1,677 ) Foreign currency translation (188 ) 132 (56 ) July 31, 2016 $ 27,650 $ (23,228 ) $ 4,422 Amortization expense — (1,520 ) (1,520 ) Foreign currency translation (214 ) 207 (7 ) July 31, 2017 $ 27,436 $ (24,541 ) $ 2,895
Schedule of Intangible Assets [Table Text Block]	Intangible assets, all finite-lived, consist of the following: July 31, 2017 July 31, 2016 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Patents $ 11,027 $ (10,951) $ 76 $ 11,027 $ (10,905) $ 122 Customer relationships 11,881 (9,083) 2,798 12,122 (8,331) 3,791 Website and acquired content 1,011 (1,011) — 1,011 (1,011) — Licensed technology and other 484 (463) 21 485 (437) 48 Trademarks 3,033 (3,033) — 3,005 (2,544) 461 Total $ 27,436 $ (24,541) $ 2,895 $ 27,650 $ (23,228) $ 4,422
Schedule of Useful Lives For Acquisitions [Table Text Block]	At July 31, 2017 information with respect to the intangibles acquired is as follows: Useful life assigned Weighted average remaining useful life Customer relationships 8-15 years 3 years Trademarks 5 years — Other intangibles 10 years 2 years
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense related to these finite-lived intangible assets for the five succeeding fiscal years ending July 31 is as follows: 2018 $ 980 2019 829 2020 501 2021 266 2022 229

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jul. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following at July 31: 2017 2016 Raw materials $ 852 $ 951 Work in process 1,905 1,755 Finished products 4,290 4,265 $ 7,047 $ 6,971

Property, plant, and equipment

Property, plant, and equipment (Tables)	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	At July 31, 2017 and 2016 property, plant, and equipment consist of: 2017 2016 Building and building improvements $ 4,898 $ 4,915 Machinery and equipment (includes asset under capital lease - see Note 9) 7,878 7,479 Office furniture and computer equipment 19,434 19,765 Leasehold improvements 5,389 5,172 37,599 37,331 Accumulated depreciation and amortization (30,410 ) (29,829 ) 7,189 7,502 Land and land improvements 712 712 $ 7,901 $ 8,214

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The (provision) benefit for income taxes for fiscal years ended July 31 is as follows: 2017 2016 2015 Current (provision) benefit: Federal $ - $ (968 ) $ — State and local (70) (276 ) (72 ) Foreign (12) (45 ) (25 ) Deferred benefit - 60 104 Benefit (provision) for income taxes $ (82) $ (1,229 ) $ 7
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements. The components of deferred tax assets (liabilities) as of July 31 are as follows: 2017 2016 Deferred tax assets: Federal tax carryforward losses $ 18,831 $ 18,964 Provision for uncollectible accounts receivable 1,392 1,406 State and local tax carry forward losses — 2,757 Accrued royalties 149 146 Stock compensation 782 616 Depreciation 804 769 Research and development and other tax credit carryforwards 2,208 2,152 Foreign tax carryforward losses 2,420 2,046 Intangibles 2,888 2,915 Inventory 2,536 2,477 Accrued expenses 1,420 1,321 Unrealized foreign exchange — 100 Other, net 69 63 Deferred tax assets 33,499 35,732 Prepaid expenses (863 ) (820 ) Other, net (55 ) — Deferred tax liabilities (918 ) (820 ) Net deferred tax assets before valuation allowance 32,581 34,912 Less: valuation allowance (32,581 ) (34,912 ) Net deferred tax liabilities $ — $ —
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	The components of income (loss) before income taxes consisted of the following for the years ended July 31: 2017 2016 2015 United States operations $ (130 ) $ 48,847 $ (615 ) International operations (2,292 ) (2,332 ) (1,677 ) Income (loss) before taxes $ (2,422 ) $ 46,515 $ (2,292 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The (provision) benefit for income taxes was at rates different from U.S. federal statutory rates for the following reasons for the years ended July 31: 2017 2016 2015 Federal statutory rate 34.0 % (34.0 )% 34.0 % Penalties and other expenses not deductible for income tax return purposes (14.5 ) (1.1 ) (18.6 ) State income taxes, net of benefit of federal tax deduction (2.1 ) (0.4 ) (0.5 ) Change in valuation allowance 64.0 32.9 (15.2 ) State tax law change (82.8 ) — — Other (2.0 ) — 0.6 (3.4 )% (2.6 )% 0.3 %

Accrued Liabilities, Other Cu32

Accrued Liabilities, Other Current Liabilities and Other Liabilities (Tables)	12 Months Ended
	Jul. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	At July 31 accrued liabilities consist of: 2017 2016 Payroll, benefits, severance and commissions $ 4,092 $ 3,956 Legal 442 954 Professional fees 599 503 Research and development 143 300 Other 1,444 2,498 $ 6,720 $ 8,211

Other liabilities (Tables)

Other liabilities (Tables)	12 Months Ended
	Jul. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Schedule of Other Liabilities [Table Text Block]	At July 31 Other liabilities consist of: 2017 2016 Accrued legal settlement – see Note 14 $ 410 $ 800 Capital lease obligation 551 794 Installment loans 22 105 $ 983 $ 1,699
Schedule Of Maturities Of Long Term Debt and Capital Lease Obligation [Table Text Block]	Future minimum lease and loan payments are as follows: Capital lease Installment loans 2018 $ 209 $ 122 2019 258 24 2020 250 — 2021 165 — Total payments 882 146 Less: interest (122 ) (2 ) Total net of interest 760 144 Less: current portion (209 ) (122 ) Other liabilities - net $ 551 $ 22

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jul. 31, 2017
Stockholders' Equity Note [Abstract]
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the activity pursuant to the Company’s stock option plans for the years ended July 31, 2017, 2016, and 2015 is as follows: 2017 2016 2015 Options Weighted - Options Weighted - Options Weighted - Outstanding at beginning of year 1,808,875 $ 3.43 1,358,104 $ 3.04 1,155,910 $ 5.03 New Grants 496,996 $ 7.07 490,473 $ 4.48 383,873 $ 3.55 Exercised (141,876 ) $ 3.19 (33,702 ) $ 2.81 — $ — Expired (33,000 ) $ 5.29 (6,000 ) $ 3.61 (181,679 ) $ 16.84 Outstanding at end of year 2,130,995 $ 4.26 1,808,875 $ 3.43 1,358,104 $ 3.04 Exercisable at end of year 1,388,475 $ 3.27 1,094,794 $ 2.95 782,688 $ 2.88 Weighted average fair value of $ 2.43 $ 1.58 $ 1.36
Schedule of Share based Compensation Stock Options Activity Range of Exercise Prices [Table Text Block]	The following table summarizes information for stock options outstanding at July 31, 2017: Options outstanding and exercisable Range of Exercise prices Shares Weighted-Average Weighted-Average $2.53 - $4.35 1,425,460 1.13 $ 3.25 $4.66 - $7.07 705,535 1.35 $ 6.31 2,130,995
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	The following table summarizes the activity pursuant to restricted stock awards for the years ended July 31, 2017 2016 2015 Awards Weighted - Awards Weighted - Awards Weighted - Outstanding at beginning of year 8,501 $ 4.13 21,501 $ 8.84 42,502 $ 5.74 Awarded 4,250 $ 6.95 — $ — 4,250 $ 4.75 Vested (5,140 ) $ (4.10 ) (11,500 ) $ (2.83 ) (19,418 ) $ (2.83 ) Forfeited (175 ) $ (2.14 ) (1,500 ) $ (2.86 ) (5,833 ) $ (3.22 ) Outstanding (non-vested) at end of year 7,436 $ 4.45 8,501 $ 4.13 21,501 $ 8.84 Weighted average market value of awards granted during year $ 6.95 $ — $ 4.75

Employee benefit plan (Tables)

Employee benefit plan (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Substantially Funded [Table Text Block]	The status of the Swiss Plan, which is substantially funded as of December 31, 2016, the latest plan year end, is as follows: As of December 31, 2016 2015 2014 Total Assets $ 2,184 $ 2,149 $ 2,132 Accumulated Benefit Obligation $ 2,432 $ 2,397 $ 2,421 Funded status 90 % 90 % 88 %
Schedule of Contributions Plan [Table Text Block]	Fiscal Year ended July 31, 2016 2015 2014 Contributions $ 224 $ 224 $ 279

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure Text Block Supplement [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Minimum future annual rentals under all non-cancellable operating leases, net of sublease rental income of $323, as of July 31, 2017, are as follows: Years ended July 31, 2018 $ 6,713 2019 6,474 2020 4,459 2021 3,146 2022 2,738 Thereafter 8,109 $ 31,639

Segment reporting (Tables)

Segment reporting (Tables)	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following financial information represents the operating results of the reportable segments of the Company: Year ended July 31, 2017 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 77,407 — — — $ 77,407 Product revenues — $ 29,192 — — 29,192 Royalty and license fee income — 1,205 — — 1,205 Total revenues 77,407 30,397 — — 107,804 Operating costs and expenses: Cost of clinical laboratory services 45,400 — — — 45,400 Cost of product revenues — 14,078 — — 14,078 Research and development — 2,311 $ 617 — 2,928 Selling, general and administrative 24,465 11,232 — $ 8,313 44,010 Provision for uncollectible accounts receivable 2,718 57 — — 2,775 Legal fee expense 146 79 — 1,454 1,679 Total operating costs and expenses 72,729 27,757 617 9,767 110,870 Operating income (loss) 4,678 2,640 (617 ) (9,767 ) (3,066 ) Other income (expense) Interest (112 ) 46 — 450 384 Other 137 (60 ) — 48 125 Foreign exchange gain — 135 — — 135 Income (loss) before taxes $ 4,703 $ 2,761 $ (617 ) $ (9,269 ) $ (2,422 ) Depreciation and amortization included above $ 1,586 $ 1,913 $ — $ 99 $ 3,598 Share-based compensation included in above: Cost of clinical laboratory services $ 6 $ — $ — $ — $ 6 Selling, general and administrative 111 74 — $ 640 825 Total $ 117 $ 74 $ — $ 640 $ 831 Capital expenditures $ 1,363 $ 390 $ — $ — $ 1,753 Year ended July 31, 2016 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 70,915 — — — $ 70,915 Product revenues — $ 30,337 — — 30,337 Royalty and license fee income — 1,521 — — 1,521 Total revenues 70,915 31,858 — — 102,773 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 42,859 — — — 42,859 Cost of product revenues — 14,331 — — 14,331 Research and development — 2,720 $ 804 — 3,524 Selling, general and administrative 22,882 11,761 — $ 8,943 43,586 Provision for uncollectible accounts receivable 2,375 (39 ) — — 2,336 Legal fee expense 134 11 — 6,239 6,384 Legal settlements, net 1,500 (58,750 ) — — (57,250 ) Total operating costs, expenses and legal settlements, net 69,750 (29,966 ) 804 15,182 55,770 Operating income (loss) 1,165 61,824 (804 ) (15,182 ) 47,003 Other income (expense) Interest (105 ) 47 — (78 ) (136 ) Other 10 38 — 74 122 Foreign exchange gain — (474 ) — — (474 ) Income (loss) before taxes $ 1,070 $ 61,435 $ (804 ) $ (15,186 ) $ 46,515 Depreciation and amortization included above $ 1,676 $ 2,091 $ — $ 73 $ 3,840 Share-based compensation included in above: Cost of clinical laboratory services $ 6 $ — $ — $ — $ 6 Selling, general and administrative 51 30 — $ 438 519 Total $ 57 $ 30 $ — $ 438 $ 525 Capital expenditures $ 1,216 $ 314 $ — $ — $ 1,530 Year ended July 31, 2015 Clinical Life Therapeutics Other Consolidated Revenues: Clinical laboratory services $ 63,414 — — — $ 63,414 Product revenues — $ 31,690 — — 31,690 Royalty and license fee income — 2,495 — — 2,495 Total revenues 63,414 34,185 — — 97,599 Operating costs, expenses and legal settlements, net: Cost of clinical laboratory services 39,589 — — — 39,589 Cost of product revenues — 15,183 — — 15,183 Research and development — 2,608 $ 742 — 3,350 Selling, general and administrative 20,666 12,168 — $ 8,235 41,069 Provision for uncollectible accounts receivable 2,418 (134 ) — — 2,284 Legal fee expense 196 (67 ) — 8,659 8,788 Legal settlements, net — (11,458 ) — — (11,458 ) Total operating costs, expenses and legal settlements, net 62,869 18,300 742 16,894 98,805 Operating (loss) income 545 15,885 (742 ) (16,894 ) (1,206 ) Other income (expense) Interest (86 ) 10 — (169 ) (245 ) Other 28 9 — 58 95 Foreign exchange gain — (936 ) — — (936 ) (Loss) income before income taxes $ 487 $ 14,968 $ (742 ) $ (17,005 ) $ (2,292 ) Depreciation and amortization included above $ 1,443 $ 2,254 $ 3 $ 89 $ 3,789 Share-based compensation included in above: Cost of clinical laboratory services $ 5 $ — — — $ 5 Research and development — 2 — — 2 Selling, general and administrative 43 15 — $ 364 422 Total $ 48 $ 17 — $ 364 $ 429 Capital expenditures $ 1,557 $ 226 — — $ 1,783
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Geographic financial information is as follows: Net sales to unaffiliated customers: 2017 2016 2015 United States $ 99,469 $ 94,016 $ 87,875 Switzerland 2,371 2,709 3,131 United Kingdom 1,673 1,730 1,904 Other international countries 4,291 4,318 4,689 Total $ 107,804 $ 102,773 $ 97,599 Long-lived assets at July 31, 2017 2016 United States $ 17,241 $ 18,730 Switzerland 649 917 United Kingdom 185 244 Other international countries 173 197 Total $ 18,248 $ 20,088
Schedule of Segment Revenue By Geographical [Table Text Block]	The following is a summary of the Life Sciences segment revenues attributable to customers located in the United States and foreign countries: 2017 2016 2015 United States $ 22,062 $ 23,102 $ 24,461 Foreign countries 8,335 8,756 9,724 $ 30,397 $ 31,858 $ 34,185

Summary of Selected Quarterly38

Summary of Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Jul. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information [Table Text Block]	Unaudited quarterly financial data for fiscal 2016 and 2015 is summarized as follows: Quarter Ended Fiscal 2017 October 31, January 31, April 30, July 31, Total revenues $ 26,284 $ 26,260 $ 27,089 $ 28,171 Gross profit 12,079 11,688 12,173 12,386 Income (loss) before income taxes (1,454 ) (1,000 ) (39 ) 71 Net income (loss) (1,474 ) (1,053 ) (71 ) 94 Basic income (loss) per common share $ (0.03 ) $ (0.02 ) $ (0.00 ) $ 0.00 Diluted income (loss) per common share (0.03 ) (0.02 ) (0.00 ) 0.00 Quarter Ended Fiscal 2016 October 31, January 31, April 30, July 31, Total revenues $ 25,177 $ 24,560 $ 26,433 $ 26,603 Gross profit 11,234 10,819 11,445 12,085 Income (loss) before income taxes 4,521 7,039 (2,113 ) 37,068 Net income (loss) 4,434 6,832 (2,115 ) 36,135 Basic income (loss) per common share $ 0.10 $ 0.15 $ (0.05 ) $ 0.78 Diluted income (loss) per common share 0.10 0.15 (0.05 ) 0.77

Summary of significant accoun39

Summary of significant accounting policies (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2017USD ($)shares	Jul. 31, 2016USD ($)shares	Jul. 31, 2015USD ($)shares	Jul. 31, 2014USD ($)
Summary of significant accounting policies (Details) [Line Items]
Number of Operating Segments	3
Cash and Cash Equivalents, at Carrying Value	$ 64,167	$ 67,777	$ 18,109	$ 17,455
Contractual Adjustment Percentage	84.00%	84.00%	85.00%
Percentage of Doubtful Accounts to Accounts Receivable	19.10%	19.40%
Finite-Lived Intangible Asset, Useful Life	10 years
Impairment of Long-Lived Assets Held-for-use	$ 0	$ 0	$ 0
Advertising Expense	649	$ 601	556
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares		449,000
Share-based Compensation	831	$ 525	429
Excess Tax Benefit from Share-based Compensation, Operating Activities		$ 0	$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 1,187
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	17 months
Clinical Labs [Member]
Summary of significant accounting policies (Details) [Line Items]
Sales Revenue Services Net Percentage	100.00%	100.00%	100.00%
Receivable Percentage	75.00%	71.00%
Life Sciences [Member]
Summary of significant accounting policies (Details) [Line Items]
Royalties Receivable	$ 400	$ 500
Minimum [Member]
Summary of significant accounting policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years
Maximum [Member]
Summary of significant accounting policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
United Health Care of New York [Member] | Clinical Labs [Member]
Summary of significant accounting policies (Details) [Line Items]
Sales Revenue Services Net Percentage	39.00%	30.00%	28.00%
Unvested Restricted Stock [Member] | In the Money Stock Options [Member]
Summary of significant accounting policies (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares	961,000		403,000
Outstanding Options [Member]
Summary of significant accounting policies (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares) | shares	0	282,000	977,000
Building and Building Improvements [Member] | Minimum [Member]
Summary of significant accounting policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Building and Building Improvements [Member] | Maximum [Member]
Summary of significant accounting policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Machinery and Equipment [Member] | Minimum [Member]
Summary of significant accounting policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment [Member] | Maximum [Member]
Summary of significant accounting policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Foreign Bank [Member]
Summary of significant accounting policies (Details) [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 500	$ 500

Summary of significant accoun40

Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 77,407	$ 70,915	$ 63,414
Clinical Labs [Member]
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 77,407	$ 70,915	$ 63,414
Sales Revenue Services Net Percentage	100.00%	100.00%	100.00%
Clinical Labs [Member] | Third-Party Payor [Member]
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 43,059	$ 34,454	$ 30,685
Sales Revenue Services Net Percentage	56.00%	49.00%	49.00%
Clinical Labs [Member] | Self-Pay [Member]
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 11,380	$ 14,744	$ 11,028
Sales Revenue Services Net Percentage	15.00%	21.00%	17.00%
Clinical Labs [Member] | Medicare [Member]
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 12,705	$ 11,392	$ 11,981
Sales Revenue Services Net Percentage	16.00%	16.00%	19.00%
Clinical Labs [Member] | Health Maintenance Organizations [Member]
Summary of significant accounting policies (Details) - Segment's net revenues and revenue percentages [Line Items]
Sales Revenue Services Net	$ 10,263	$ 10,325	$ 9,720
Sales Revenue Services Net Percentage	13.00%	14.00%	15.00%

Summary of significant accoun41

Summary of significant accounting policies (Details) - Net accounts receivable by segment - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 15,180	$ 14,592
Clinical Labs [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 11,401	$ 10,364
Accounts Receivable Net Current Percentage	100.00%	100.00%
Clinical Labs [Member] | Third-Party Payor [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 7,256	$ 5,861
Accounts Receivable Net Current Percentage	64.00%	57.00%
Clinical Labs [Member] | Self-Pay [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 1,591	$ 1,676
Accounts Receivable Net Current Percentage	14.00%	16.00%
Clinical Labs [Member] | Medicare [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 1,385	$ 1,486
Accounts Receivable Net Current Percentage	12.00%	14.00%
Clinical Labs [Member] | Health Maintenance Organizations [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 1,169	$ 1,341
Accounts Receivable Net Current Percentage	10.00%	13.00%
Life Sciences [Member]
Summary of significant accounting policies (Details) - Net accounts receivable by segment [Line Items]
Accounts Receivable Net Current	$ 3,779	$ 4,228

Summary of significant accoun42

Summary of significant accounting policies (Details) - Allowance for doubtful accounts - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Allowance for doubtful accounts [Abstract]
Beginning balance	$ 3,517	$ 1,786
Provision for doubtful accounts	2,775	2,336	$ 2,284
Write-offs	(2,716)	(605)
Ending balance	$ 3,576	$ 3,517	$ 1,786

Summary of significant accoun43

Summary of significant accounting policies (Details) - Computation of basic and diluted net loss per share - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Computation of basic and diluted net loss per share [Abstract]
Net (loss) income (in Dollars)	$ 94	$ (71)	$ (1,053)	$ (1,474)	$ 36,135	$ (2,115)	$ 6,832	$ 4,434	$ (2,504)	$ 45,286	$ (2,285)
Weighted-average common shares outstanding - basic									46,350	46,153	45,355
Add: effect of dilutive stock options and restricted stock										449
Weighted-average common shares outstanding - diluted									46,350	46,602	45,355
Net (loss) income per share – basic (in Dollars per share)	$ 0	$ 0	$ (0.02)	$ (0.03)	$ 0.78	$ (0.05)	$ 0.15	$ 0.10	$ (0.05)	$ 0.98	$ (0.05)
Net (loss) income per share – diluted (in Dollars per share)	$ 0	$ 0	$ (0.02)	$ (0.03)	$ 0.77	$ (0.05)	$ 0.15	$ 0.10	$ (0.05)	$ 0.97	$ (0.05)

Summary of significant accoun44

Summary of significant accounting policies (Details) - Amount of expense related to share-based payment arrangements - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share Based Compensation	$ 831	$ 525	$ 429
Cost of Clinical Laboratory Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share Based Compensation	6	6	5
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share Based Compensation			2
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share Based Compensation	$ 825	$ 519	$ 422

Goodwill and intangible asset45

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Goodwill and intangible assets (Details) [Line Items]
Goodwill	$ 7,452	$ 7,452
Finite-Lived Intangible Asset, Useful Life	10 years
Amortization of Intangible Assets	$ 1,520	$ 1,677	$ 1,770
Intangible Assets, Amortization Period [Member]
Goodwill and intangible assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	2 years

Goodwill and intangible asset46

Goodwill and intangible assets (Details) - Schedule of indefinite-lived intangible assets - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Indefinite-lived Intangible Assets [Line Items]
Gross	$ 27,436	$ 27,650
Accumulated Amortization	(24,541)	(23,228)
Net	2,895	4,422
Amortization expense, Accumulated Amortization	(1,520)	(1,677)	$ (1,770)
Amortization expense, Net	(1,520)	(1,677)	(1,770)
Life Sciences [Member]
Indefinite-lived Intangible Assets [Line Items]
Gross	27,436	27,650	27,838
Accumulated Amortization	(24,541)	(23,228)	(21,683)
Net	2,895	4,422	$ 6,155
Amortization expense, Accumulated Amortization	(1,520)	(1,677)
Amortization expense, Net	(1,520)	(1,677)
Foreign currency translation, Gross	(214)	(188)
Foreign currency translation, Accumulated Amortization	207	132
Foreign currency translation, Net	$ (7)	$ (56)

Goodwill and intangible asset47

Goodwill and intangible assets (Details) - Schedule of intangible assets - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,436	$ 27,650
Finite-lived intangible assets, Accumulated Amortization	(24,541)	(23,228)
Finite-lived intangible assets, Net	2,895	4,422
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(10,951)	(10,905)
Finite-lived intangible assets, Net	76	122
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	11,881	12,122
Finite-lived intangible assets, Accumulated Amortization	(9,083)	(8,331)
Finite-lived intangible assets, Net	2,798	3,791
Website And Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	1,011	1,011
Finite-lived intangible assets, Accumulated Amortization	(1,011)	(1,011)
Licensed Technology And Other [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	484	485
Finite-lived intangible assets, Accumulated Amortization	(463)	(437)
Finite-lived intangible assets, Net	21	48
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of intangible assets [Line Items]
Finite-lived intangible assets, Gross	3,033	3,005
Finite-lived intangible assets, Accumulated Amortization	$ (3,033)	(2,544)
Finite-lived intangible assets, Net		$ 461

Goodwill and intangible asset48

Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions	12 Months Ended
	Jul. 31, 2017
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Weighted average remaining useful life	3 years
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	5 years
Other Intangible Assets [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	10 years
Weighted average remaining useful life	2 years
Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	4 years
Minimum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years
Maximum [Member] | Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of useful lives for acquisitions [Line Items]
Useful life assigned	15 years

Goodwill and intangible asset49

Goodwill and intangible assets (Details) - Schedule of finite-lived intangible assets, future amortization expense $ in Thousands	Jul. 31, 2017USD ($)
Schedule of finite-lived intangible assets, future amortization expense [Abstract]
2,018	$ 980
2,019	829
2,020	501
2,021	266
2,022	$ 229

Supplemental disclosure for s50

Supplemental disclosure for statement of cash flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Income Taxes Paid	$ 1,021	$ 279	$ 115
Interest Paid	119	121	206
Installment Loans Financed Amount	69	95	346
Capital Lease Obligation Cost Basis		1,280	155
Adjustment to Additional Paid in Capital Stock Option Issued in Lieu of Cash Payment	$ 0	$ 0	$ 45

Inventories (Details) - Schedul

Inventories (Details) - Schedule of inventory, current - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Schedule of inventory, current [Abstract]
Raw materials	$ 852	$ 951
Work in process	1,905	1,755
Finished products	4,290	4,265
	$ 7,047	$ 6,971

Property, plant, and equipmen52

Property, plant, and equipment (Details) - Schedule of property, plant and equipment - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Schedule of property, plant and equipment [Abstract]
Building and building improvements	$ 4,898	$ 4,915
Machinery and equipment (includes asset under capital lease - see Note 9)	7,878	7,479
Office furniture and computer equipment	19,434	19,765
Leasehold improvements	5,389	5,172
	37,599	37,331
Accumulated depreciation and amortization	(30,410)	(29,829)
	7,189	7,502
Land and land improvements	712	712
	$ 7,901	$ 8,214

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income taxes (Details) [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2,300	$ 14,700
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	56,200
Deferred Tax Assets Research and Development and Other Tax Credit Carryforwards	2,208	$ 2,152
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	1,100
Foreign Loss Carryforwards	9,300
Undistributed Earnings of Foreign Subsidiaries	87
Liability for Uncertain Tax Position	0
U.S. Federal Tax [Member]
Income taxes (Details) [Line Items]
Deferred Tax Assets Research and Development and Other Tax Credit Carryforwards	$ 1,100
Minimum [Member] | Domestic Tax Authority [Member]
Income taxes (Details) [Line Items]
Operating Loss Carryforwards Expiration Year	2,030
Minimum [Member] | Research Tax Credit Carryforward [Member]
Income taxes (Details) [Line Items]
Tax Credit Carryforward Expiration Year	2,025
Maximum [Member] | Domestic Tax Authority [Member]
Income taxes (Details) [Line Items]
Operating Loss Carryforwards Expiration Year	2,035
Maximum [Member] | Research Tax Credit Carryforward [Member]
Income taxes (Details) [Line Items]
Tax Credit Carryforward Expiration Year	2,037

Income taxes (Details) - (Provi

Income taxes (Details) - (Provision) Benefit for income taxes - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Current (provision) benefit:
Federal		$ (968)
State and local	$ (70)	(276)	$ (72)
Foreign	(12)	(45)	(25)
Deferred benefit		60	104
Benefit (provision) for income taxes	$ (82)	$ (1,229)	$ 7

Income taxes (Details) - Compon

Income taxes (Details) - Components of deferred tax assets (liabilities) - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Deferred tax assets:
Federal tax carryforward losses	$ 18,831	$ 18,964
Provision for uncollectible accounts receivable	1,392	1,406
State and local tax carry forward losses		2,757
Accrued royalties	149	146
Stock compensation	782	616
Depreciation	804	769
Research and development and other tax credit carryforwards	2,208	2,152
Foreign tax carryforward losses	2,420	2,046
Intangibles	2,888	2,915
Inventory	2,536	2,477
Accrued expenses	1,420	1,321
Unrealized foreign exchange		100
Other, net	69	63
Deferred tax assets	33,499	35,732
Prepaid expenses	(863)	(820)
Other, net	(55)
Deferred tax liabilities	(918)	(820)
Net deferred tax assets before valuation allowance	32,581	34,912
Less: valuation allowance	$ (32,581)	$ (34,912)

Income taxes (Details) - Comp56

Income taxes (Details) - Components of income (loss) before income taxes - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Income taxes (Details) - Components of income (loss) before income taxes [Line Items]
Income (loss) before taxes	$ 71	$ (39)	$ (1,000)	$ (1,454)	$ 37,068	$ (2,113)	$ 7,039	$ 4,521	$ (2,422)	$ 46,515	$ (2,292)
Domestic Tax Authority [Member]
Income taxes (Details) - Components of income (loss) before income taxes [Line Items]
Income (loss) before taxes									(130)	48,847	(615)
Foreign Tax Authority [Member]
Income taxes (Details) - Components of income (loss) before income taxes [Line Items]
Income (loss) before taxes									$ (2,292)	$ (2,332)	$ (1,677)

Income taxes (Details) - (Pro57

Income taxes (Details) - (Provision) Benefit for income taxes were at rates different from U.S. federal statutory rates	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
(Provision) Benefit for income taxes were at rates different from U.S. federal statutory rates [Abstract]
Federal statutory rate	34.00%	(34.00%)	34.00%
Penalties and other expenses not deductible for income tax return purposes	(14.50%)	(1.10%)	(18.60%)
State income taxes, net of benefit of federal tax deduction	(2.10%)	(0.40%)	(0.50%)
Change in valuation allowance	64.00%	32.90%	(15.20%)
State tax law change	(82.80%)
Other	(2.00%)		0.60%
	(3.40%)	(2.60%)	0.30%

Loan Payable (Details)

Loan Payable (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Debt Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 8,000
Line of Credit Facility Additional Borrowings Capacity	4,000
Unamortized Debt Issuance Expense	281
Unamortized Debt Issuance Cost Included in Prepaid Expenses	$ 0	$ 28
Nominal Interest Rate	5.25%	5.25%
Debt Instrument, Interest Rate During Period	14.30%	11.40%
Line of Credit Facility Expiration Month and Year	December 7, 2016

Accrued Liabilities, Other Cu59

Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - USD ($) $ in Millions	Jul. 31, 2017	Jul. 31, 2016
Payables and Accruals [Abstract]
Self Insurance Reserve, Current	$ 0.3	$ 0.3

Accrued Liabilities, Other Cu60

Accrued Liabilities, Other Current Liabilities and Other Liabilities (Details) - Schedule of Accrued liabilities - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Schedule of Accrued liabilities [Abstract]
Payroll, benefits, severance and commissions	$ 4,092	$ 3,956
Legal	442	954
Professional fees	599	503
Research and development	143	300
Other	1,444	2,498
	$ 6,720	$ 8,211

Other liabilities (Details)

Other liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation (in Dollars)	$ 517
Capital Lease Interest Rate Range Start	4.25%
Capital Lease Interest Rate Range End	9.50%
Short-term Debt, Weighted Average Interest Rate, at Point in Time	7.50%	8.00%

Other liabilities (Details) - S

Other liabilities (Details) - Schedule of other liabilities - USD ($) $ in Thousands	Jul. 31, 2017	Jul. 31, 2016
Other liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 983	$ 1,699
Accrued Legal Settlement [Member]
Other liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	410	800
Capital Lease Obligations [Member]
Other liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	551	794
Installment Loans [Member]
Other liabilities (Details) - Schedule of other liabilities [Line Items]
Other liabilities	$ 22	$ 105

Other liabilities (Details) -63

Other liabilities (Details) - Schedule of future minimum lease and loan payments $ in Thousands	Jul. 31, 2017USD ($)
Schedule of future minimum lease and loan payments [Abstract]
2,018	$ 209
2,018	122
2,019	24
2,019	258
2,020	250
2,021	165
Total payments	882
Total payments	146
Less: interest	(122)
Less: interest	(2)
Total net of interest	760
Total net of interest	144
Less: current portion	(209)
Less: current portion	(122)
Other liabilities - net	551
Other liabilities - net	$ 22

Stockholders' Equity (Details)

Stockholders' Equity (Details)	Jan. 05, 2017USD ($)$ / sharesshares	Jan. 06, 2016USD ($)$ / sharesshares	Mar. 14, 2014USD ($)$ / sharesshares	Jun. 16, 2016USD ($)$ / sharesshares	Jan. 21, 2015USD ($)$ / sharesshares	Jul. 31, 2017USD ($)$ / sharesshares	Jul. 31, 2016USD ($)$ / sharesshares	Jul. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014shares	Jan. 14, 2011shares
Stockholders' Equity (Details) [Line Items]
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares						$ 0.01	$ 0.01
Percentage of Commission Payable on Equity Offering						3.00%
Maximum Offering Price Under Sales Agreement						20,000,000			20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | $						$ 10,530,000	$ 4,399,000	$ 97,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars) | $						14,510,000	6,451,000	$ 154,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars) | $						$ 1,388,000	$ 64,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						496,996	490,473	383,873
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares						$ 7.07	$ 4.48	$ 3.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares						$ 2.43	$ 1.58	$ 1.36
Senior Officers and Board of Directors [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years				2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	264,896				293,373
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 7.07				$ 3.40
Share Based Compensation Arrangement by Share Based Payment Award Options Term	5 years				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares	$ 2.40				$ 1,270,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 3 months				3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	46.28%				52.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.48%				0.93%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $	$ 0				$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	0
Number of Officers					2
Senior Management and Employees [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	229,100		191,600
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 7.07		$ 4.35
Share Based Compensation Arrangement by Share Based Payment Award Options Term	5 years		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares	$ 2.48		$ 1.57
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 6 months		3 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	45.85%		48.14%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.54%		1.24%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $	$ 0		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	0		61,366
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares			6,167
Senior Officers [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			110,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares			$ 4.35
Share Based Compensation Arrangement by Share Based Payment Award Options Term			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares			$ 1.46
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			46.13%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.19%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $			$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			55,000
Employees [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				2,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares				$ 5.61
Share Based Compensation Arrangement by Share Based Payment Award Options Term				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares				$ 1.88
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				46.64%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				0.846%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $				$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				1,000
Board of Directors [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		189,873
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares		$ 4.66
Share Based Compensation Arrangement by Share Based Payment Award Options Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares		$ 1.65
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		3 years 3 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		48.60%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.31%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		126,582
Executive Officers [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share) | $ / shares						$ 3.40
Share Based Compensation Arrangement by Share Based Payment Award Options Term						5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $ / shares						$ 1.39
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						55.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						1.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments (in Dollars) | $						$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						23,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares						5,000
2005 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized						1,000,000
Share Based Compensation Arrangement by Share Based Payment Award Number of Additional Awards to be Granted						0
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units										3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						350,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Authorized Common Stock that may be Issued and Sold Under Sales Agreement (in Dollars) | $						$ 19,150,000
Securities That May Be Sold Under The Agreement (in Dollars) | $						$ 150,000,000
Stock Issued During Period, Shares, Employee Benefit Plan						91,541	160,352	214,984
Payments of Stock Issuance Costs (in Dollars) | $						$ 724,000	$ 709,000	$ 662,000
Minimum [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years
Maximum [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Number of Shares of Common Stock Remain Available for Issuance as Option for Plan Termination						0
Restricted Stock [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | $						$ 44,000	$ 46,000	$ 79,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of stock option plans - $ / shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Schedule of stock option plans [Abstract]
Outstanding at beginning of year (in Shares)	1,808,875	1,358,104	1,155,910
Outstanding at beginning of year	$ 3.43	$ 3.04	$ 5.03
New Grants (in Shares)	496,996	490,473	383,873
New Grants	$ 7.07	$ 4.48	$ 3.55
Exercised (in Shares)	(141,876)	(33,702)
Exercised	$ 3.19	$ 2.81
Expired (in Shares)	(33,000)	(6,000)	(181,679)
Expired	$ 5.29	$ 3.61	$ 16.84
Outstanding at end of year (in Shares)	2,130,995	1,808,875	1,358,104
Outstanding at end of year	$ 4.26	$ 3.43	$ 3.04
Exercisable at end of year (in Shares)	1,388,475	1,094,794	782,688
Exercisable at end of year	$ 3.27	$ 2.95	$ 2.88
Weighted average fair value of options granted during year	$ 2.43	$ 1.58	$ 1.36

Stockholders' Equity (Details66

Stockholders' Equity (Details) - Schedule of stock options outstanding - $ / shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2014
Stockholders' Equity (Details) - Schedule of stock options outstanding [Line Items]
Shares (in Shares)	2,130,995	1,808,875	1,358,104	1,155,910
Weighted-Average Exercise Price (in Dollars per share)	$ 4.26	$ 3.43	$ 3.04	$ 5.03
Exercise Price Range 1 [Member]
Stockholders' Equity (Details) - Schedule of stock options outstanding [Line Items]
Range of Exercise prices	2.53
Range of Exercise prices	$ 4.35
Shares (in Shares)	1,425,460
Weighted-Average Remaining Contractual Life in years	1 year 47 days
Weighted-Average Exercise Price (in Dollars per share)	$ 3.25
Exercise Price Range 2 [Member]
Stockholders' Equity (Details) - Schedule of stock options outstanding [Line Items]
Range of Exercise prices	4.66
Range of Exercise prices	$ 7.07
Shares (in Shares)	705,535
Weighted-Average Remaining Contractual Life in years	1 year 127 days
Weighted-Average Exercise Price (in Dollars per share)	$ 6.31

Stockholders' Equity (Details67

Stockholders' Equity (Details) - Schedule of restricted stock awards - $ / shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Schedule of restricted stock awards [Abstract]
Outstanding at beginning of year (in Shares)	8,501	21,501	42,502
Outstanding at beginning of year	$ 4.13	$ 8.84	$ 5.74
Awarded	$ 6.95		$ 4.75
Awarded (in Shares)	4,250		4,250
Vested (in Shares)	(5,140)	(11,500)	(19,418)
Vested	$ (4.10)	$ (2.83)	$ (2.83)
Forfeited (in Shares)	(175)	(1,500)	(5,833)
Forfeited	$ (2.14)	$ (2.86)	$ (3.22)
Outstanding (non-vested) at end of year (in Shares)	7,436	8,501	21,501
Outstanding (non-vested) at end of year	$ 4.45	$ 4.13	$ 8.84
Weighted average market value of awards granted during year	$ 6.95		$ 4.75

Employee benefit plan (Details)

Employee benefit plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Employee benefit plan (Details) [Line Items]
Employer Matched Contributions Percentage Of The Employees Contribution	50.00%	50.00%	50.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	10.00%	10.00%	10.00%
Share Based 401k Employer Match Expense (in Dollars)	$ 724	$ 709	$ 662
Defined Benefit Plan, Contribution in Accrued Liabilities (in Dollars)	$ 412	$ 413	$ 387
Defined Contribution Plan Minimum Annual Contribution Percent	13.00%
Minimum Age of Employee for Saving Contribution	25 years
Defined Benefit Plan Minimum Annual Investment Return Percentage	1.00%
Defined Contribution Pension Plan Expiration Date	Dec. 31, 2019
Swiss Employees [Member]
Employee benefit plan (Details) [Line Items]
Employer Matched Contributions Percentage Of The Employees Contribution	50.00%

Employee benefit plan (Detail69

Employee benefit plan (Details) - Schedule of substantially funded - USD ($) $ in Thousands	Jul. 31, 2017	Dec. 31, 2016	Jul. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of substantially funded [Abstract]
Total Assets	$ 107,665	$ 2,184	$ 111,821	$ 2,149	$ 2,132
Accumulated Benefit Obligation		$ 2,432		$ 2,397	$ 2,421
Funded status		90.00%		90.00%	88.00%

Employee benefit plan (Detail70

Employee benefit plan (Details) - Schedule of contrubutions plan - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2015	Jul. 31, 2014
Schedule of contrubutions plan [Abstract]
Contributions	$ 224	$ 224	$ 279

Royalty and other income (Detai

Royalty and other income (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Royalty and other income (Details) [Line Items]
Patent Expiration Date	Apr. 24, 2018
Life Sciences [Member]
Royalty and other income (Details) [Line Items]
Royalty Revenue	$ 1,205	$ 1,521	$ 2,495

Commitments (Details)

Commitments (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Commitments (Details) [Line Items]
Description Of Operating Leases	The Company leases equipment, office and laboratory space underseveral non-cancellable operating leases that expire between September 2017 and June 2028. Certain leases include renewal optionsand rent escalation clauses. An entity owned by certain executive officers/directors of the Company owns the building that theCompany leases as its main facility for clinical laboratory operations and certain research operations. In addition to the minimumannual rentals of space, the lease is subject to annual increases, based on the consumer price index. Annual increases are limitedto 3% per year.
Maximum Annual Rental Increase Percentage	3.00%
Rent expense Including Real Estate Taxes	$ 1,752	$ 1,704	$ 1,623
Amount of Real Estate Tax Abatement Received		61	61
Operating Leases, Rent Expense	4,658	$ 4,572	$ 4,504
Operating Leases, Rent Expense, Sublease Rentals	$ 323
Agreement Renew Period	2 years
Other Commitment, Due in Next Twelve Months	$ 2,498
Minimum [Member]
Commitments (Details) [Line Items]
Lease Expiration Month and Year	September 2,017
Maximum [Member]
Commitments (Details) [Line Items]
Lease Expiration Month and Year	June 2,028

Commitments (Details) - Schedul

Commitments (Details) - Schedule of future minimum rental payments for operating leases $ in Thousands	Jul. 31, 2017USD ($)
Schedule of future minimum rental payments for operating leases [Abstract]
2,018	$ 6,713
2,019	6,474
2,020	4,459
2,021	3,146
2,022	2,738
Thereafter	8,109
	$ 31,639

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended							12 Months Ended
	Jul. 31, 2016USD ($)	May 31, 2016USD ($)	Jan. 31, 2016USD ($)	Oct. 31, 2015USD ($)	Jan. 31, 2014USD ($)	Nov. 30, 2012	Jun. 30, 2004	Jul. 31, 2017USD ($)	Jul. 31, 2016USD ($)	Jul. 31, 2014USD ($)	Jun. 30, 2014USD ($)
Contingencies (Details) [Line Items]
Gain Contingency, Patents Allegedly Infringed upon, Number							6
Number of Licensee Patents								4
Gain Contingency, Patents Found Not Infringed upon, Number						1
Gain Contingencies Prejudgement Interest					$ 12.5
Period Over Which Settlement Amount Has to Be Paid										5 years
Number of Pending Cases								7
Subpoena [Member]
Contingencies (Details) [Line Items]
Estimated Litigation Settlement Amount										$ 2
Additional Payment of Litigation Settlement Amount									$ 1.5
Total Liability For Settlement Agreement								$ 0.8
Current Liability For Settlement Agreement								0.4
Other Liability For Settlement Agreement								$ 0.4
Perkin Elmer [Member]
Contingencies (Details) [Line Items]
Escrow Deposit											$ 7
Litigation Settlement, Amount Awarded from Other Party			$ 7
Affymetrix Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements				$ 6.8
Agilent Technologies, Inc. [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements			$ 6.1
Life Technologies Corporation [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements		$ 24.3
Illumina Inc [Member]
Contingencies (Details) [Line Items]
Payments for Legal Settlements	$ 14.5
Clinical Labs [Member]
Contingencies (Details) [Line Items]
Percentage of Cost Incurred in Using Third Party Premises								18.00%
Indemnification Agreement [Member]
Contingencies (Details) [Line Items]
Gain Contingency, Unrecorded Amount								$ 48.5

Segment reporting (Details)

Segment reporting (Details)	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Number of Reportable Segments	3
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	100.00%

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of segment reporting information, by segment - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Segment Reporting Information [Line Items]
Clinical laboratory services	$ 77,407	$ 70,915	$ 63,414
Product revenues	29,192	30,337	31,690
Royalty and license fee income	1,205	1,521	2,495
Total revenues	107,804	102,773	97,599
Cost of clinical laboratory services	45,400	42,859	39,589
Cost of product revenues	14,078	14,331	15,183
Research and development	2,928	3,524	3,350
Selling, general and administrative	44,010	43,586	41,069
Provision for uncollectible accounts receivable	2,775	2,336	2,284
Legal fee expense	1,679	6,384	8,788
Legal settlements, net		(57,250)	(11,458)
Operating income (loss)	(3,066)	47,003	(1,206)
Other	125	122	95
Foreign exchange gain	135	(474)	(936)
Clinical Labs [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	77,407	70,915	63,414
Total revenues	77,407	70,915	63,414
Cost of clinical laboratory services	45,400	42,859	39,589
Selling, general and administrative	24,465	22,882	20,666
Provision for uncollectible accounts receivable	2,718	2,375	2,418
Legal fee expense	146	134	196
Legal settlements, net		1,500
Total operating costs and expenses	72,729	69,750	62,869
Operating income (loss)	4,678	1,165	545
Interest	(112)	(105)	(86)
Other	137	10	28
Income (loss) before taxes	4,703	1,070	487
Depreciation and amortization included above	1,586	1,676	1,443
Capital expenditures	1,363	1,216	1,557
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	6	6	5
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	111	51	43
Clinical Labs [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	117	57	48
Life Sciences [Member]
Segment Reporting Information [Line Items]
Product revenues	29,192	30,337	31,690
Royalty and license fee income	1,205	1,521	2,495
Total revenues	30,397	31,858	34,185
Cost of product revenues	14,078	14,331	15,183
Research and development	2,311	2,720	2,608
Selling, general and administrative	11,232	11,761	12,168
Provision for uncollectible accounts receivable	57	(39)	(134)
Legal fee expense	79	11	(67)
Legal settlements, net		(58,750)	(11,458)
Total operating costs and expenses	27,757	(29,966)	18,300
Operating income (loss)	2,640	61,824	15,885
Interest	46	47	10
Other	(60)	38	9
Foreign exchange gain	135	(474)	(936)
Income (loss) before taxes	2,761	61,435	14,968
Depreciation and amortization included above	1,913	2,091	2,254
Capital expenditures	390	314	226
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	74	30	15
Life Sciences [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	74	30	17
Life Sciences [Member] | Research and Development Expense [Member]
Segment Reporting Information [Line Items]
Share-based compensation			2
Therapeutics [Member]
Segment Reporting Information [Line Items]
Research and development	617	804	742
Total operating costs and expenses	617	804	742
Operating income (loss)	(617)	(804)	(742)
Income (loss) before taxes	(617)	(804)	(742)
Depreciation and amortization included above			3
Other Segments [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	8,313	8,943	8,235
Legal fee expense	1,454	6,239	8,659
Total operating costs and expenses	9,767	15,182	16,894
Operating income (loss)	(9,767)	(15,182)	(16,894)
Interest	450	(78)	(169)
Other	48	74	58
Income (loss) before taxes	(9,269)	(15,186)	(17,005)
Depreciation and amortization included above	99	73	89
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	640	438	364
Other Segments [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	640	438	364
Consolidated [Member]
Segment Reporting Information [Line Items]
Clinical laboratory services	77,407	70,915	63,414
Product revenues	29,192	30,337	31,690
Royalty and license fee income	1,205	1,521	2,495
Total revenues	107,804	102,773	97,599
Cost of clinical laboratory services	45,400	42,859	39,589
Cost of product revenues	14,078	14,331	15,183
Research and development	2,928	3,524	3,350
Selling, general and administrative	44,010	43,586	41,069
Provision for uncollectible accounts receivable	2,775	2,336	2,284
Legal fee expense	1,679	6,384	8,788
Legal settlements, net		(57,250)	(11,458)
Total operating costs and expenses	110,870	55,770	98,805
Operating income (loss)	(3,066)	47,003	(1,206)
Interest	384	(136)	(245)
Other	125	122	95
Foreign exchange gain	135	(474)	(936)
Income (loss) before taxes	(2,422)	46,515	(2,292)
Depreciation and amortization included above	3,598	3,840	3,789
Capital expenditures	1,753	1,530	1,783
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]
Segment Reporting Information [Line Items]
Share-based compensation	6	6	5
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Share-based compensation	825	519	422
Consolidated [Member] | Total [Member]
Segment Reporting Information [Line Items]
Share-based compensation	$ 831	$ 525	429
Consolidated [Member] | Research and Development Expense [Member]
Segment Reporting Information [Line Items]
Share-based compensation			$ 2

Segment reporting (Details) - G

Segment reporting (Details) - Geographic financial information - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales to unaffiliated customers	$ 107,804	$ 102,773	$ 97,599
Long-lived assets	18,248	20,088
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales to unaffiliated customers	99,469	94,016	87,875
Long-lived assets	17,241	18,730
SWITZERLAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales to unaffiliated customers	2,371	2,709	3,131
Long-lived assets	649	917
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales to unaffiliated customers	1,673	1,730	1,904
Long-lived assets	185	244
Other International Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales to unaffiliated customers	4,291	4,318	$ 4,689
Long-lived assets	$ 173	$ 197

Segment reporting (Details) -78

Segment reporting (Details) - Schedule of segment revenue by geographical - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items]
Sales Revenue Net	$ 107,804	$ 102,773	$ 97,599
UNITED STATES
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items]
Sales Revenue Net	99,469	94,016	87,875
Life Sciences [Member]
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items]
Sales Revenue Net	30,397	31,858	34,185
Life Sciences [Member] | UNITED STATES
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items]
Sales Revenue Net	22,062	23,102	24,461
Life Sciences [Member] | Foreign Countries [Member]
Segment reporting (Details) - Schedule of segment revenue by geographical [Line Items]
Sales Revenue Net	$ 8,335	$ 8,756	$ 9,724

Summary of Selected Quarterly79

Summary of Selected Quarterly Financial Data (unaudited) (Details) - Quarterly Financial Data - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jul. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Oct. 31, 2016	Jul. 31, 2016	Apr. 30, 2016	Jan. 31, 2016	Oct. 31, 2015	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Quarterly Financial Data [Abstract]
Total revenues	$ 28,171	$ 27,089	$ 26,260	$ 26,284	$ 26,603	$ 26,433	$ 24,560	$ 25,177
Gross profit	12,386	12,173	11,688	12,079	12,085	11,445	10,819	11,234
Income (loss) before income taxes	71	(39)	(1,000)	(1,454)	37,068	(2,113)	7,039	4,521	$ (2,422)	$ 46,515	$ (2,292)
Net income (loss)	$ 94	$ (71)	$ (1,053)	$ (1,474)	$ 36,135	$ (2,115)	$ 6,832	$ 4,434	$ (2,504)	$ 45,286	$ (2,285)
Basic income (loss) per common share (in Dollars per share)	$ 0	$ 0	$ (0.02)	$ (0.03)	$ 0.78	$ (0.05)	$ 0.15	$ 0.10	$ (0.05)	$ 0.98	$ (0.05)
Diluted income (loss) per common share (in Dollars per share)	$ 0	$ 0	$ (0.02)	$ (0.03)	$ 0.77	$ (0.05)	$ 0.15	$ 0.10	$ (0.05)	$ 0.97	$ (0.05)

SCHEDULE II VALUATION AND QUA80

SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts - USD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Allowance for Doubtful Accounts [Member]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts [Line Items]
Balance at Beginning of period		$ 3,517	$ 1,786	$ 2,142
Charged (credited) to costs and expenses		2,775	2,336	2,284
Deductions	[1]	2,716	605	2,640
Balance at end of period		3,576	3,517	1,786
Valuation Allowance of Deferred Tax Assets [Member]
SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS (Details) - Schedule of Valuation and Qualifying Accounts [Line Items]
Balance at Beginning of period		34,912	49,658	49,465
Charged (credited) to costs and expenses		(2,179)	(14,746)	193
Balance at end of period		$ 32,733	$ 34,912	$ 49,658
[1]	Write-off of uncollectible accounts receivable.